Page 11234..1020..»

Where Is Your Money Really Going During IVF? | BabyGaga – BabyGaga

IVF is expensive! Here's a break-down of all the costs associated with the fertility process, which explains why it's so pricey in the first place.

Infertility is a tough emotional and physical experience and a record number of families are using Invitro Fertilization (IVF) to have babies. A report by Pew Research Center suggests that the number of assisted reproductive technology (ART) births in the UShas gone up threefold since 1996. Moreover, one in three American adults has used or knows someone who has sought after some form of fertility treatment. That is 12.7% of women aged 15-49, as stated by the CDC. IVF is the most popular form of ART treatment which apparently, is more expensive in the United States than anywhere else.

View this post on Instagram

Have you ever wondered how embryos are created in the lab? ( ): Using Standard IVF means to place both gametes, previously treated to facilitate this process, together in a petri dish. We let nature do its part and spermatozoon will run to the oocyte in the culture media drops and, if everything goes well, one day later we will have a zygote (the single cell made by the fusion of both gametes). ( ): With this process, we take every spermatozoon one by one, after a proper process, and we physically inject it inside the oocyte emulating thus the natural process. If everything goes well, one day later we will have the zygote. This zygote with only one cell will start cleavage and will increase its cell number day by day. Thus, on the day 2 of the embryo, we expect to have, average, 2-4 cells, on the 3rd day, average, 6-12, on day 4 cells should start compacting and become a new structure called Morula and fifth day, we should have a blastocyst. Feel free to ask additional questions and check our webpage - #ivfjourney #ivf #invitro #invitrofertilization #fertility #fertilityjourney #embryo #health #georgia

A post shared by GeoMedicalART (@geomedicalart) on Jul 2, 2020 at 12:05am PDT

IVF is a fertility treatment that uses a female's eggs and a male's sperm. The process involves combining the extracted egg and retrieved sperm in a laboratory dish. The mixture forms an embryo in a process called insemination, and the fertilized is then transferred to your uterus, three to five days after fertilization.

This ART technique is applied to treat infertility patients who have male factor infertility, unexplained sterility, blocked or injured fallopian tubes, ovulation illnesses, and couples with genetic disorders.

RELATED: Paid Surrogacy Is Illegal In Canada - What Other Fertility Options Are There?

Figures from Advanced Fertility Care shows that live birth success rates in the US for each IVF round is 54.9% for patients below 35 years. The percentage decreases as a person gets older, with patients below 40 years having a success rate of 21.2% and those above 42 years achieving zero live births.

In the United States, the average cost for one IVF round is $12,000 without including the cost of medication. However, the cost varies and may be as high as $15,000 or as low as $10,000. Likewise, the cost of the medication ranges between excesses of $3,000 andas low as$1,500. Thus, on average, a patient can spend up to $20,000 for one IVF cycle, and up to $60,000 for three full IVF cycles.

The treatment is quite pricy primarily because the process involves many stages of preparation before, and after the treatment that tallies up over time. Patients pay for the IVF procedure itself, in addition to regular consultations, hormone medications, and the prospect of having to undergo more than one IVF cycle.

Many factors determine the cost of IVF, which includes the patients age, medical history, and the type of procedure. The costs from the procedure are determined by the injectables, specialist care, egg and sperm retrieval, genetic testing, insemination, storing and caring for the fertilized egg (embryo), and so on. Additionally, a patients personal choices can affect the cost as well. For instance, if a person has a low pain threshold, there will be an extra cost for getting sedated or anesthetized for egg retrieval.

On the whole, finances are a big consideration when it comes to IVF, which takes 10 t0 12 days of medication, and an additional five days to grow the embryo and placing it inside the uterus. The most expensive part of IVF is when a couple opts for a pregnancy carrier. If you add the legal and agency fees, IVF costs, and reimbursement to the pregnancy carrier, the cost can vary from a low of $50,000 to a high of $100,000.

Resorting to an IVF can look like too big a step, but there are ways you can save money on IVF.

Do A Mini-IVF.The bulk of expenses for IVF treatments go to the injectables used to stimulate the growth of an egg. This medication can be very pricy, but there is a way of doing IVF with fewer meds through Mini-IVF, short for minimal stimulation IVF. Although Mini-IVF has not caught on in America, it is a procedure that reduces IVF treatment costs by using much fewer injectables. However, this method is not recommended for everyone as it could lessen the chances of success for some. Therefore, seek guidance from a clinic that specializes in the procedure if you choose Mini-IVF treatment.

Thorough Financial Planning.How much money will you need? Get detailed information concerning every aspect of the treatment and cost. You will need to know what is factored into the total cost and what is not counted in. Then, begin saving months before, and read your insurance plan to see if you are eligible for partial coverage.

Choosing An IVF Clinic.Find the clinic that will provide the treatment you need at a price you can afford. Likewise, find a clinic that offers exceptional treatment packages with guarantees and great success rates, to avoid having to undergo more than one IVF round.

NEXT:Celebrities You Didn't Know Had Fertility Issues


Shawn Johnson Blames Past Drug Use & Eating Disorder For Her Miscarriage

I have been a writer since 2012, and have enjoyed the journey thus far. When I am not busy writing like there's no tomorrow, I enjoy spending time with my three daughters and watching Netflix.

Read more here:
Where Is Your Money Really Going During IVF? | BabyGaga - BabyGaga

Recommendation and review posted by Bethany Smith

Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic –

Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic

Continued here:
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic -

Recommendation and review posted by Bethany Smith

Earlier diagnosis and better treatment for type 1 diabetes – Advanced Science News

Nanotechnology is poised to revolutionize the diagnosis and treatment of patients with type 1 diabetes.

According to the WHO, in 2016, an estimated 1.6 million deaths were directly caused by diabetes. It is a chronic disease that occurs when the body is unable to produce or process a hormone called insulin, which helps regulate blood sugar levels.

Of the three major types, type 1 diabetes has proven to be the most problematic in terms of providing patients with a timely diagnosis, as patients may be asymptomatic for long periods of time with a sudden onset of symptoms well into the diseases progression.

Currently, type 1 diabetes can be diagnosed at any age, but it is mostly found in children and adolescents. Once diagnosed, patients also have a high risk of diabetes-related complications, as well as other autoimmune diseases, such as hashimotos thyroiditis or celiac disease. Therefore, early diagnosis and treatment could prevent the progression of type 1 diabetes.

At present, the diagnosis of type 1 diabetes depends on the detection of blood glucose levels and islet autoantibodies, which are markers that appear when insulin producing islet cells clusters of hormone producing cells in the pancreas are damaged. But the function of the patients cells have likely already been severely damaged by the time they receive a diagnosis.

As more and more people suffer from type 1 diabetes of the 422 million people worldwide diagnosed with diabetes in 2016, roughly 5% were categorized as type 1 the importance of early diagnosis and the urgency of effective treatments becomes ever more important. However, recent medical methods for the early diagnosis of type 1 diabetes are still limited. So, its important to develop new methods for early diagnosis and treatment.

Nanomedicine is an emerging field and provides a promising and more effective alternative to diagnose type 1 diabetes, and stands to revolutionize treatment for patients. Experts in this field, Dr. Yuanzeng Min from the School of Chemistry and Material Science at the University of Science and Technology of China (USTC) and Dr. Jianping Weng, a clinician from the First Affiliated Hospital of USTC discuss the findings in a recent reviewpublished in WIREs Nanomedicine and Nanobiotechnology.

Magnetic resonance imaging (MRI) has in itself revolutionized imaging in medicine. It takes advantage of powerful magnets to make a detailed internal picture of the body and helps doctors diagnose otherwise unseen disease or injury. To improve this technique and make it more suitable to diagnosing patients with type 1 diabetes, scientists have explored using common biomarkers of the disease, such as inflammation, and enhancing physicians ability to detect them in MRI analysis using helper materials. In this sense, nanomaterials have been shown great promise in facilitating the accumulation of imaging substrates at the targeted site, thus improving the quality of MRI imaging and the accuracy of diagnosis.

An excellent example of this is the clinical use of the nanoparticle ferumoxtran-10 or ferumoxytol. In clinical studies, there was an observed increase in pancreatic accumulation of this imaging nanoparticle in inflamed islets of type 1 diabetes patients in comparison to a healthy control group. This method is non-invasive, and the imaging materials are readily metabolized by the body without harmful side effects. This technique has been ground-breaking in visualizing insulitis, an inflammatory lesion and an early stage marker of type 1 diabetes.

Type 1 diabetes is classified as an autoimmune disease in which insulin-producing cells are destroyed by the bodys own immune system, and is affected by a number of factors, such as genetics, environment and metabolism, among others. The downregulation of the overactive immune cells that kill the insulin-producing cells has been gathering more and more attention in the medical and research community.

Studies have shown that nanoparticles have the beneficial characteristics of high drug loading and are capable of being targeted to a specific location in the body, minimizing harmful side effects usually observed in these types of therapies. Scientists have used loaded nanoparticles to carry antigenic peptides or pMHC (peptide major histocompatibility complex) to suppress the bodys immune response so that the immune cells no longer attack cells. Research has also explored encapsulating cytokines or other synthesized molecules to modulate the immune system into the nanoparticles, which could be locally administered along with modulating immune cells, such as T cells or APCs (antigen presenting cells).

Significant progress in the development of sophisticated nanotechnologies has also been seen in the past 10 years for immunotherapy and islet transplantation in type 1 diabetes. Nanotechnology has played a significant role in islet transplantation by encapsulating healthy cells with biomaterials as most of the insulin-producing cells are destroyed by the patients own immune system. The biomaterials also protect the transplanted cells from immune exclusion. In addition to avoiding a deleterious host response, encapsulated islets must receive an adequate nutrient supply and positive extracellular cues in order to survive and functionin vivo.Thus, while using nanotechnology to encapsulate cells, it alsorequires as little interference as possible with the generation of new blood vessels in the encapsulation. This is usually achieved by improving the mechanical rigidity, charge distribution, morphology, and other related parameters of the nanomaterials.

While great strides have been made, limitations in the application of nanotechnology in diagnosis and treatment of type 1 diabetes remain. For example, some nanoparticles are not specifically target islets, their production process can be complicated, and the cost is high. However, their application in this area of medicine has only just begun, and we are beginning to see the benefits of this research in clinical trials.

With research in type 1 diabetes and the development of nanotechnology, these problems will hopefully one day be solved. We believe that in the next 10-20 years there will be high chance of this type of therapy used regularly in the clinical diagnosis and treatment oftype 1 diabetes patients.

Written by: Yuanzeng Min and Jianping Weng

Reference: Wen Pan, et al. Nanotechnologys application in Type 1 diabetes. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1645

View original post here:
Earlier diagnosis and better treatment for type 1 diabetes - Advanced Science News

Recommendation and review posted by Bethany Smith

Going through menopause increases risk of depression in 70% women, says study – Times of India

Depression has been shown to be prevalent during menopause, affecting as many as 70 per cent of women transitioning into menopause, say researchers.The study, published in the journal of The North American Menopause Society (NAMS), not only confirms the high prevalence of depression but also the greatest risk factors for it in postmenopausal women, as well as any relationships with anxiety and fear of death. "The findings are consistent with existing literature and emphasize the high prevalence of depressive symptoms in midlife women, particularly those with a history of depression or anxiety and chronic health conditions," said study researcher Stephanie Faubion, NAMS medical director.With the decrease in hormone production during menopause, women are more prone to a number of psychological problems, including depression, anxiety, irritability, nervousness, sadness, restlessness, memory problems, lack of confidence and concentration, and a loss of libido.

At the same time, as women age, the fear of death becomes more pronounced.

Depression and anxiety, which are the most common psychological problems that occur during the menopause transition, likely increase that fear, the researchers said.

For the current findings, the research team picked 485 postmenopausal Turkish women aged between 35 and 78 years.

The researchers sought to determine the frequency of depressive symptoms in postmenopausal women, the variables affecting it, and the levels of anxiety and fear of death.

They then evaluated the relationship between all these variables and postmenopausal depression.

They found that depression in postmenopausal women is a common and important health problem that requires further study.

In this specific study, 41 per cent of the participants were confirmed to experience some form of depression.


Read more from the original source:
Going through menopause increases risk of depression in 70% women, says study - Times of India

Recommendation and review posted by Bethany Smith

Doctors Day 2020: Four pandemic heroes share how they maintain their work-life balance and keep themselves h – TheHealthSite

Today the whole world is focusing only on COVID-19 pandemic. The virus is the common topic now for every discussion, either official or non-official. But most of these talks are about COVID-19 patients and the potential drugs. And hardly anybody talk about the emotional and physical challenges that doctors on COVID-19 duty are going through, or for that matter, their health. Today, India is celebrating the National Doctors Day to acknowledge the services of doctors and their huge contribution to medical advancement. The day is also observed to pay tribute to legendary physician Dr. Bidhan Chandra Roy (Dr. B C Roy), who was also the second Chief Minister of West Bengal. As we thank doctors for providing us with selfless service and health care today, lets also asked them about their health, and how are theyre managing the work and family life amidst the pandemic. Also Read - Doctors' Day 2020: Help your doctor treat you better in the era of teleconsultation

We have spoken to four doctors a cardiologist, a pulmonologist, a diabetologist and a general practitioner to get a rough idea about what doctors are doing to maintain their work-life balance and keep themselves strong and healthy amidst the pandemic. Here is what the four doctors say: Also Read - Doctors Day 2020: Expert tips for patients and physicians to get along with each other

Dr. TS Kler is the Chairman of PSRI Heart Institute in Delhi and a recipient of the prestigious Padma Bhushan Award. Prior to this, Dr. Kler has served as Head of Cardiac Sciences Department at the Fortis Flt Lt Rajan Dhall Hospital in Vasant Kunj. Lets hear from him about things he does to stay healthy and the challenges he is facing amidst the pandemic. Also Read - Doctors Day 2020: What do physicians fear and expect while treating COVID-19 patients?

Things you do to maintain work-life balance: As far as maintaining work-life balance is concerned, my formula is simple, have a positive attitude towards life and then everything becomes easier. I dont take unnecessary worries, worrying too much is a pathological reaction. If you keep worrying about things, your performance decreases, your decision-making abilities become poor. On the other hand, when your mind is free from worries, you think rationally in any given situation that may help you deal with any problem in life. Similar is my attitude with COVID-19, which a big challenge for everybody. Yes, the chances of getting exposed to the virus are much more for doctors and health care workers as compared to others, but you have to take that challenge. I have been going to the hospital throughout the lockdown period without taking a single day leave. Im a cardiologist and there are always patients who need urgent care and they cannot be left alone. There are always emergency cases. We are also offering telemedicine options for those who dont need hospitalization. In my family, there are only four us my wife and our two sons. My wife is also a doctor and she is also playing a huge role in fighting the COVID-19 pandemic. My elder son is an engineer and my younger son is also a doctor and he has been posted in the COVID ward. As there are three doctors in the family, the evening discussion is mostly on COVID nowadays. And we all understand the demands of our job as a doctor and our responsibilities towards society. In fact, I keep telling my colleagues that we dont have any excuses at all to be scared of COVID or not to go to the hospital and see patients. If our patients need us, we have to go and see them.

Things you do to keep your heart healthy: I walk at least 10 km a day. I use an app called health application that records how much I have walked daily, every month and every year. So, based on the figure shown in this app, last year I walked 3842 km, which is more than the distance from Srinagar to Kanyakumari. You can do exercise any time whichever convenient for you but I prefer the morning time. I get up at 5 am in the morning and by 5:45 am I am out in the park. Exercise to me is a passion, its my addiction. I also do yoga regularly. We organize a regular yoga programme in my home, three days a week. When it comes to diet, I eat a lot of green vegetables and fruits. I am a non-vegetarian but I keep non-veg consumption very low. Neither I smoke nor do I allow anybody in the family to smoke in my home. The rest, be happy, stay positive, and help others, this can make a lot of difference in your health too. Helping others is actually good for your overall health. Your generosity will not only bring about a change in others life but I believe that it produces some special hormone in your body which gives you a lot of satisfaction, improves your mental wellbeing and make you strong in life.

Dr. Anoop Misra is the Chairman of Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. He is also the Chairman of National Diabetes, Obesity and Cholesterol Foundation (N-DOC), and Vice President of Diabetes Foundation (India) (DFI).

Things you do to maintain your work-life balance: I maintain a strict discipline so as to compartmentalize time for work and then personal life and do regular exercise to enable augmentation of clear thinking and generate ideas. Another thing that I do to keep a balance between my work and family life is planning my day ahead. Much of my days planning is done while listening to music or exercising outdoors. Also, I always try to think of ways to increase the efficiency of the workforce, so as to achieve daily objectives in a shorter time and save time for home. Everybody should have some me time to relax, it allows your mind and body to repair. For me relaxation time in the evening is sacrosanct; I avoid phone calls during this time.

Things you do to keep your blood sugar levels under control: There are simple things that I do keep sugar and blood pressure under control, and keep my heart ticking regularly. In short, to keep myself fit. There is no magic mantra in following these rules. And I would like all people to follow the same to avoid diabetes, hypertension or heart disease; and those who are patients, to manage the conditions effectively.

Dr. Nikhil Modi is a well-known Pulmonologist with experience of more than 13 years. Presently he is working as a Consultant in the Department of Respiratory, Critical care, and Sleep medicine at Indraprastha Apollo Hospital, New Delhi.

Things you do to maintain your work-life balance: First and foremost work comes first in any situation and so I make sure that I am available whenever my patients need me. At the same time, your family is also important and so I try to spend as much quality time as possible with them, whenever I dont have any emergency case. Also, those times spend with your family also act as a stress buster. Thats why it important to give equal importance to work and life. But in this situation, our patients need me more than my family and I am committed to my work.

Things you to keep your lungs healthy: When it comes to keeping myself fit and my lungs healthy, it starts from early morning with exercises like yoga or walking, followed by a healthy and heavy breakfast. Since doctors are quite busy these days, I dont get much time for exercise but whenever I get time, I do some sort of exercise. When youre going in a place where you have to see patients who are infected with COVID-19, you have to be strong from inside too. Frequent small meals also help provide the nutrients your body needs to keep the immune system strong. The most important thing to keep your lungs healthy is to stay away from smoking and pollution. If you can do yoga and deep breathing for at least 10 minutes daily, its the best you can do to your lungs.

Dr. Pulin Kumar Gupta is currently associated as Professor (Medicine), Ram Manohar Lohia Hospital, Delhi.

Things you do to maintain your work-life balance: These days due to the COVID-19 pandemic, theres no fixed timing for our work. I leave for the hospital at 8 and but then you dont know when our work will end. If I am able to reach home early like 7 in the evening, I always spend some time with my kids, have dinner with them, or play an indoor game. Thats how I try to maintain my work-life balance. Since I am on COVID-19 duty these days, I also take all the necessary precautions like keeping my shoes outside, changing my clothes immediately after reaching home, and taking a bath. For the safety of my family, I stay in a separate room and avoid doing certain things that I used to do before the pandemic like kissing my kids.

Things you to keep yourself healthy: A healthy diet is a must to stay healthy and its more important now. My diet includes lots of protein, like boiled eggs, paneer, and soybean. I also eat 30 gm of almond and lots of fruit. There is very little fat in my diet. I drink turmeric milk twice daily in the morning and at night to boost my immunity. I also make sure that I drink plenty of water and limit alcohol intake. In the evening I walk on my treadmill for about 45 minutes daily. In the hospital, during lunchtime I play table tennis with my colleagues. Thats how I try my best to keep myself healthy during this pandemic.

Published : July 1, 2020 10:48 am | Updated:July 1, 2020 11:12 am

See the original post:
Doctors Day 2020: Four pandemic heroes share how they maintain their work-life balance and keep themselves h - TheHealthSite

Recommendation and review posted by Bethany Smith

Im A Physician Who Had Breast Cancer, And Here Are The Knowledge-Based Decisions I Made For Myself – Scary Mommy

Scary Mommy and Westend61/Getty

So, 2020 has really been a shit year.

It has been for nearly everyone, of course, and when the stuff stops hitting the fan, we all need to take a collective breath, pat ourselves on the back, and celebrate.

I had a busy year planned for 2020: Im a gynecologic surgeon seeing patients and trying to build a badly needed menopause clinic in a local hospital here in Seattle. Im editing a book, and consulting and providing telemedicine care for women in menopause as Chief Medical Officer at Gennev.

But then in January, I got a diagnosis of breast cancer, and suddenly I was making new plans. Somehow I had to carve out five weeks from this life to recover from a double mastectomy, then more time later for recovery from reconstruction. I managed it, barely, to have my first surgery in March.

I thought I had it pretty much under control. My patients were scheduled with other physicians, meetings were on hold, a bunch of work up-front meant I could relax and heal. In February, I went on a vacation to Mexico, where I spent a lot of time crying on beaches and into margaritas with friends. It helped. I came back ready to move forward.

And then COVID-19 hit, and it hit right here at home: epicenter, Seattle.

Suddenly the chaos and noise of my own life have expanded to a global level, and all of us in health care are scrambling to find answers, help others stay calm and safe, keep ourselves as safe as possible on the front lines, and meanwhile Im trying desperately to ignore the little voice inside thats saying, What about me?

As a physician and surgeon, I know what cancer looks like. I have an idea how it progresses and how bad treatment can be. I wanted to get on with it, have the surgery and whatever treatment so I could recover and get back to my life. But with my first surgery scheduled for mid-March, now it looked like those carefully extracted five weeks werent mine anymore.

Oh, and did I mention, suddenly my kids were home all the time? Theyre pretty much grown, so I have it easier than many, but the advanced clusterf*ck of trying to home school an attention-deficit high schooler while sympathizing with my college kid who was missing out on some pretty important stuff in her education and future career (shes a dancer) deflated any zen I managed to scrape together in a hurry.

This is a tough time for teens and young adults who rely on their social structures more than ever, and suddenly mine were stuck with a sick mom and Zoom.

Despite being a pretty practical person, I havent always approached my health practically. It wasnt until I was diagnosed as pre-diabetic at 42 that I finally started taking some things seriously. Perimenopause had added some belly fat and bumped up my bad cholesterol, so I at last started exercising regularly and taking medication, since eating better wasnt enough anymore.

However, as someone with a family history of cancers, Im a huge advocate of screening and started annual mammograms at 40.

Now thats irony, Alanis.

As with most women in their 40s, the mammograms showed that I had dense breasts, but nothing particularly concerning.

Then Gennev started working with MiraKind, an organization researching the connection between a gene defect called the KRAS variant and a greater likelihood of developing certain cancers. I got tested, and sure enough, I was a carrier. Knowing being KRAS positive could mean I was more susceptible to breast cancer, I added an MRI to my usual mammogram (remember, dense breasts).

Two days later, they called me and said, So, there are a couple of masses on your MRI. A couple of biopsies revealed invasive ductal carcinoma. More testing, more biopsies, more black and blue boobs.

Now I had a decision to make: I could get bilateral lumpectomies and sign up for a life of going in every six months and probably having to get biopsies every six months. Eventually theyd find something, and Id be right back here again. Im a doctor I knew how Id feel with these things on my chest, knowing there was cancer in them. So I decided on a bilateral mastectomy.

In the end, it was the right choice: there was more cancer that hadnt yet been detected. It was small, sure; but it wouldnt always be small.

The hospital where I would have my surgery started disallowing non-essential surgery the week before my mastectomy was planned. And surgery on anyone who was medically fragile old, ill, likely to respond poorly to anesthesia, etc. was postponed.

I wanted nothing to do with postponing the surgery. I had done everything to make taking those five weeks okay for everyone it affected patients, family, colleagues. Just the thought of redoing all that was exhausting. I had taken the time to take care of me, and dammit, I was going to take care of me!

In the end, it came down to the fact that I was young and healthy going in, so I wouldnt need an ICU bed that was needed for a COVID-19 patient. Id be out the next day. So we went ahead.

On March 19, all my breast tissue was removed.

March and April were spent alternating holding my breath and breathing sighs of relief: biopsy of sentinal nodes revealed no signs of spreading. Testing of the tumor showed it wasnt aggressive enough to require chemotherapy. Because I did what I did when I did it, the cancer was Stage 1. Ill be treated with hormone therapy; Im on Tamoxifen. They got great margins when they did the surgery, and I dont need radiation.

Ask anyone who knows me: Im pretty blunt. Im never unkind, but if a patient wants a lot of touchy-feely handholding, they should probably find another doctor. However. Telling your daughters you have breast cancer is not an occasion for blunt.

Not only was I telling them I was sick, I also knew they would watch me for signs of what was to come for them. Realistic but reassuring is a delicate dance. Fortunately, I was able to be pretty reassuring. It was Stage 1, not a particularly aggressive form, and Id be fine on the other side. But I also wanted to be honest with them about their own health and the screenings theyd need, given their family history.

I could complain about how unfair it is to have bad genetics, or how much it sucks to take care of myself and still have cancer, but I really have a shit happens approach to life, and it served me well. Yelling about how unfair it is as much as I was screaming it on the inside sometimes wasnt going to help me or my kids get through it.

COVID and being isolated together certainly didnt make it easier. This is a hard time for kids their lives are dominated by social things, the groups theyre in, who they communicate with, the things they do. Theyre missing out on things. So managing their emotions and my own is really tough; Im maybe not as patient as I would be otherwise, because Im going through some shit. I have cancer and it sucks. I dont tell them everything because it wouldnt help them. But I try to be open and honest because I know your imagination can sometimes be worse than the truth.

It could be easy to let cancer and COVID take charge and send me screaming to a safe room, but thats really not my style. I take precautions to protect myself from the coronavirus, but Im still seeing patients. I know that as a healthcare professional, Ill get it eventually. I just intend to be at full strength when it happens.

I walk every day, three to five miles with my dog. I run three days a week. Im back in physical therapy because too many hours performing surgery have caused problems with my neck. I truly think staying active has helped with my recovery.

Recovery was tough, not so much because of pain, but because COVID meant my friends and family couldnt help the way they wanted to: they couldnt come clean my house or cook meals, though many dropped meals on my doorstep, rang the bell and ran.

I have two sisters who live locally, and it was killing them not to be able to come and help. One sis is a chef and she just wanted to come and cook for me, but she couldnt come into my house. That was hard, but honestly, it was harder for them than me, since I was pretty out of it for the first two weeks after surgery.

So, yeah, 2020 is a shit year, but at least some things will get easier now. No more mammograms for me, because the reconstruction surgery scheduled for July will be done using my own abdominal tissue. From now on, a check up involves making sure the area around the reconstruction is healthy and cancer-free, including the lymph nodes and chest wall.

I know a lot about health, particularly womens health, because its my job. And I made a lot of decisions, together with my doctors, based on the knowledge I have. I wanted to share a few things that might help others have an easier time of it, COVID or no.

It might not prevent you from having health problems, but being fit can make it easier to handle the treatment and make recovery easier and faster.

Diabetes, cancer, heart disease are all in my family history. Knowing that helped me make better choices. And the KRAS test prompted me to do the MRI that revealed the cancer while it was still early-stage. Knowledge matters.

When I got that pre-diabetes diagnosis, I decided it was time to get a handle on me Ive spent my life caring for others as a doctor, wife, and mom. I was trained in residency to go until you drop. But suddenly I realized I needed to focus on my own health too. I made changes in work and home life, ate better, took meds. I wanted to feel good and I did. And when this came up, I had good endurance, strong muscles, a strong cardiovascular system, even strong legs and abs to help me get out of bed when I couldnt use my arms!

For the past few years, I had managed my sleep patterns to feel better, and through all of this, I managed to for the most part still get good sleep.

Because I made great decisions for a solid few years before this diagnosis, there was a little WTF? that I did everything right and still got this disease. But we live in a toxic world, I hadnt always made great decisions, my work has at times been really stressful, plus, I just had some bad dumb luck. Theres always been that bit of pessimism in me because my family history indicates that I have at least one cancer in my future. But, I thought, this can be dealt with, Im healthy going in, and Ill take this one day at a time.

Ive lost sensation in my chest area. I bump into things, and I dont even know it. Its weird, and Im mourning the loss of sensation there, but I knew it would happen, and I was at least somewhat prepared. Make plans. Have a wedge for your bed. Know what the drain looks like coming out of your body. Know who will help you shower and who will make you laugh when your life just has so much yuck in it. Because theres a lot of yuck; youre going to need your sense of humor. And if yours is AWOL, borrow some from a friend.

Just because I knew what was coming doesnt mean I didnt have emotions around it. I had to let myself grieve the loss of my breasts even as I was taking control of the decision to have the bilateral mastectomy. I had to stop being practical and allow myself to mourn.

Living in Seattle, I am blessed with having so many amazing medical professionals in cancer treatment. But I also wanted to work with someone I was comfortable with, someone I trusted with my body, with my future. I needed to feel they were making decisions that worked for me. Please know that youre not hurting a doctors feelings if you decide to move on from them because youre not connecting well with them. It happens all the time, and docs understand how important it is that you feel comfortable. I picked people I felt great with and felt we were making decisions for the same reasons.

Hey, I get a tummy tuck out of this get lemons, make lemonade! Im not exactly going to be voluptuous, but Im good with Bs or even really big As that look nice.

Dont rely on self-breast exams even when I knew where my biggest tumor was, I couldnt feel it. Also, some people are pushing thermograms, claiming theyre safer than mammograms, but they are NOT safer, so do your research before committing. A mammogram isnt perfect, but its a good tool and has saved lives. And you wont get breast cancer from mammograms. The radiation is minimal: you get more from walking around for two weeks in the world. Be informed about your choices before you make them.

I could have put off the reconstruction until next year, when theres a chance COVID-19 will be behind us, and things will be back to whatever normal there is on the other side. But I figured, 2020 is already a hot mess of a year, I might as well shove all the shit into this one and look forward to 2021.

So thats what Im doing. May you get all your shit behind you too. Now go schedule your next screening.

Go here to see the original:
Im A Physician Who Had Breast Cancer, And Here Are The Knowledge-Based Decisions I Made For Myself - Scary Mommy

Recommendation and review posted by Bethany Smith

Rare genital malformations in women’s health research: sociodemographic, regional, and disease-related characteristics of patients with…

Folch M, Pigem I, Konje JC. Mllerian agenesis: etiology, diagnosis, and management. Obstet Gynecol Surv. 2000;55:6449.

CAS PubMed Google Scholar

Brucker SY, Oppelt P, Ludwig KS, Wallwiener D, Beckmann MW. Vaginale und uterine Fehlbildungen Teil 2 Geburtshilfe Frauenheilkd. 2005; 66 (11): R221-R224.

Londra L, Chuong FS, Kolp L. Mayer-Rokitansky-Kuster-Hauser syndrome: a review. Int J Womens Health. 2015;7:86570.

PubMed PubMed Central Google Scholar

Morcel K, Guerrier D, Watrin T, Pellerin I, Levque J. The Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome: clinical description and genetics [article in French]. J Gynecol Obstet Biol Reprod (Paris). 2008;37:53946.

CAS Google Scholar

Carranza-Lira S, Forbin K, Martinez-Chquer JC. Rokitansky syndrome and MURCS association--clinical features and basis for diagnosis. Int J Fertil Womens Med. 1999;44(5):2505.

CAS PubMed Google Scholar

Morcel K, Dallapiccola B, Pasquier L, Watrin T, Bernardini L, Guerrier D. Mayer-Rokitansky-Kster-Hauser syndrome. Eur J Hum Genet. 2012;20(2):13.

Google Scholar

Lermann J, Mueller A, Wiesinger E, Hberle L, Brucker S, Wallwiener D, Dittrich R, Renner SP, Beckmann MW, Oppelt PG. Comparison of different diagnostic procedures for the staging of malformations associated with Mayer-Rokitansky-Kster-Hauser syndrome. Fertil Steril. 2011;96(1):1569.

PubMed Google Scholar

Patnaik SS, Brazile B, Dandolu V, Ryan PL, Liao J. Mayer-Rokitansky-Kster-Hauser (MRKH) syndrome: a historical perspective. Gene. 2015;555(1):3340.

CAS PubMed Google Scholar

Pai A, Shakir M. Mayer-Rokitansky-Kuster-Hauser syndrome type II: A rare case. Indian J Hum Genet. 2013 Jan;19(1):1135.

PubMed PubMed Central Google Scholar

Nakum A, Kumawat K, Chauhan H, Parikh JV. Mayer-Rokitansky-Kuster-Hauser (MRKH) Syndrome Type 2: Atypical Presentation of Rare Case. Natl J Med Res. 2013;3(4):40911.

Google Scholar

Dragusin R, Tudorache , Surlin V, Lichiardopol C, Iliescu DG. Importance of Laparoscopic Assessment of the Uterine Adnexa in a Mayer-Rokitansky-Kuster-Hauser Syndrome Type II Case. Curr Health Sci J. 2014;40(2):1447.

PubMed PubMed Central Google Scholar

Raybaud C, Richard O, Arzim M, David M. Mayer-Rokitansky-Kster-Hauser syndrome: associated pathologies. Arch Pediatr. 2001;8:120913.

CAS PubMed Google Scholar

Braun-Quentin C, Billes C, Bowing B, Kotzot D. MURCS association: case report and review. J Med Genet. 1996;33:61820.

CAS PubMed PubMed Central Google Scholar

Oppelt P, Renner SP, Kellermann A, et al. Clinical aspects of Mayer-Rokitansky-Kuester-Hauser syndrome: recommendations for clinical diagnosis and staging. Humanit Rep. 2006;21:792.

Google Scholar

Hofstetter G, Concin N, Marth C, Rinne T, Erdel M, Janecke A. Genetic analyses in a variant of Mayer-Rokitansky-Kuster-Hauser syndrome (MURCS association). Wien Klein Wochenschr. 2008;120(13-14):4359.

CAS Google Scholar

Rall KK, Eisenbeis S, Henninger V, Henes M, Wallwiener D, Bonin M, Brucker S. Typical and Atypical Associated Findings in a Group of 346 Patients with Mayer-Rokitansky-Kuester-Hauser Syndrome. J Pediatr Adolesc Gynecol. 2015;28(5):362836.

PubMed Google Scholar

Bungartz J. Das MRKH-Syndrom: Klinik, Analyse der Fehldiagnosen und Entwicklung eines Leitfadens zur Differenzialdiagnostik und zur Vermeidung von Malpractice. Medizinische Fakultt Tbingen 2012; Dissertation.

Wottgen M, Brucker S, Renner SP, Strissel PL, Strick R, Kellermann A, Wallwiener D, Beckmann MW, Oppelt P. Higher incidence of linked malformations in siblings of Mayer-Rokitansky-Kster-Hauser syndrome patients. Hum Reprod. 2008;23(5):122631.

CAS PubMed Google Scholar

Ledig S, Schippert C, Strick R, Beckmann MW, Oppelt PG, Wieacker P. Recurrent aberrations identified by array-CGH in patients with Mayer-Rokitansky-Kster-Hauser syndrome. Fertil Steril. 2011;95(5):158994.

CAS PubMed Google Scholar

Rall KK, Eisenbeis S, Barresi G, Rckner D, Walter M, Poths S, Wallwiener D, Riess O, Bonin M, Brucker S. Mayer-Rokitansky-Kster-Hauser syndrome discordance in monozygotic twins: matrix metalloproteinase 14, low-density lipoprotein receptor-related protein 10, extracellular matrix, and neoangiogenesis genes identified as candidate genes in a tissue-specific mosaicism. Fertil Steril. 2015;103(2):494502.

CAS PubMed Google Scholar

Guerrier D, Mouchel T, Pasquier L, Pellerin I. The Mayer-Rokitansky-Kster-Hauser syndrome (congenital absence of uterus and vagina)--phenotypic manifestations and genetic approaches. J Negat Results Biomed. 2006;5:1. .

Hohl MK. Modernes Management der angeborenen (Mayer-Rokitansky-Kster-Hauser-Syndrom, MRKH) und erworbenen Vaginalaplasie. Frauenheilkunde aktuell. 2007;1:412.

Google Scholar

Rall KK, Brucker S. Die drei A der Vaginalaplasie kein differentialdiagnostisches Chamleon. Frauenarzt. 2007;48(10):9408.

Google Scholar

Aittomaki K, Eroila H, Kajanoja P. A population-based study of the incidence of mullerian aplasia in Finland. Fertil Steril. 2001;76(3):6245.

CAS PubMed Google Scholar

Master-Hunter T, Heiman TL. Amenorrhea: Evaluation and Treatment. Am Fam Phys. 2006;73(8):137482.

Google Scholar

Heller-Boersma JG, Schmidt UH, Edmonds DK. Psychological distress in women with uterovaginal agenesis (Mayer-Rokitansky-Kster-Hauser syndrome, MRKH). Psychosomatics. 2009;50:27781.

PubMed Google Scholar

Bean EJ, Mazur T, Robinson AD. Mayer-Rokitansky-Kster-Hauser syndrome: sexuality, psychological effects and quality of life. J Pediatr Adolesc Gynecol. 2009;22:33946.

CAS PubMed Google Scholar

Krupp K, Fliegner M, Brunner F, Brucker SY, Rall KK, Richter-Appelt H. Quality of Life and Psychological Distress in Women with Mayer-Rokitansky-Kster-Hauser Syndrome and Individuals with Complete Androgen Insensitivity Syndrome. Open J Med Psychol. 2014;3:21221.

Google Scholar

Schffeler N, Brucker SY, Rall KK, Zipfel S. Psychological strains in patients with MRKHS and psychosomatic support. Conference Paper. J Psychosom Obstetr Gynecol. 2010;31:46.

Google Scholar

Kimberley N, Hutson JM, Southwell BR, Grover SR. Well-being and sexual function outcomes in women with vaginalagenesis. Fertil Steril. 2011;95(1):23841.

PubMed Google Scholar

ACOG Committee Opinion. Vaginal agenesis: Diagnosis, Management and Routine Care. Obstet Gynecol. 2006;108(6):16059.

Google Scholar

Rall KK, Schickner MC, Barresi G, Schnfisch B, Wallwiener M, Wallwiener CW, Wallwiener D, Brucker SY. Laparoscopically assisted neovaginoplasty in vaginal agenesis: a long-term outcome study in 240 patients. J Pediatr Adolesc Gynecol. 2014;27(6):37985.

PubMed Google Scholar

Brucker SY, Gegusch M, Zubke W, Rall K, Gauwerky JF, Wallwiener D. Neovagina creation in vaginal agenesis: development of a new laparoscopic Vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril. 2008;90(5):194052.

PubMed Google Scholar

Brucker SY, Rall K, Campo R, Oppelt P, Isaacson K. Treatment of congenial malformations. Semin Reprod Med. 2011;29(2):10112.

PubMed Google Scholar

Nippert I. Frauengesundheitsforschung und gender based medicine. In: Cottmann A, Kotendieck B, Schildmann U, editors. Das undisziplinierte Geschlecht. Frauen und Geschlechterforschung Einblick und Ausblick. Wiesbaden: VS Verlag; 2000. p. 5167.

Google Scholar

Regitz-Zagrosek V. Sex and gender differences in health. Science & society series on sex and science. EMBO Reports. 2012;13:596603.

CAS PubMed PubMed Central Google Scholar

Pfaff H. Versorgungsforschung Begriffsbestimmung, Gegenstand und Aufgaben. In: Pfaff H, et al., editors. Gesundheitsversorgung und Disease Management Grundlagen und Anwendungen der Versorgungsforschung. Bern: Hans Huber Verlag; 2003. p. 1323.

Google Scholar

Crowley R, Wolfe I, Lock K, McKee M. Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Childhood. 2011;96(6):54853.

CAS Google Scholar

Lugasi T, Achille M, Stevenson M. Patients perspective on factors that facilitate transition from child-centered to adult-centered health care: a theory integrated metasummary of quantitative and qualitative studies. J Adolesc Health. 2011;48(5):42940.

PubMed Google Scholar

Rall KK, Wallwiener M, Rieen I, Zipfel S, Wallwiener D, Brucker S. Optimierung von Aufklrung, Betreuung und Compliance bei Patientinnen mit seltenem gynkologischen Krankheitsbildam Beispiel des Mayer-Rokitansky-Kster-Hauser-Syndroms (MRKH-Syndrom). Geburtsh Frauenheilk. 2008;68:11025.

Google Scholar

Grber-Grtz D, Kronenthaler A, Rieger MA, Rall KK, Schffeler N, Hiltner H, Ueding E, Brucker SY, Simoes E. Entwicklung eines Versorgungsmodells zur Verbesserung der Transitionsversorgung bei Seltenen Erkrankungen am Beispiel MRKH Ergebnisse einer systematischen Literaturrecherche. Meeting Abstract 12. Deutscher Kongress fr Versorgungsforschung. Berlin, 23.-25.10.2013. Dsseldorf: German Medical Science GMS Publishing House; 2013. DocPO4-1-06-213. doi: .

Wagner A, Brucker SY, Ueding E, Grber-Grtz D, Simoes E, Rall K, Kronenthaler A, Schffeler N, Rieger MA. Treatment management during the adolescent transition period of girls and young women with Mayer-Rokitansky-Kster-Hauser syndrome (MRKHS): a systematic literature review. Orphanet J Rare Dis. 2016;11(1):152 Review.

PubMed PubMed Central Google Scholar

Simoes E, Kronenthaler A, Schffeler N, Wagner A, Rall KK, Sokolov AN; Hiltner H, Ueding E, Emrich C, Psch LS, Baur MC, Gerlach F, Mohr S, Krebs E, Eissler M, Zipfel S, Rieger MA, Wallwiener D, Brucker SY. Entwicklung eines Versorgungsmodells zur Verbesserung der Transitionsversorgung bei Seltenen Erkrankungen am Beispiel weiblicher Jugendlicher mit genitaler Fehlbildung. TransCare O Schlussbericht. Tbingen 2016. URL: (Zugriff: 01.03.2017).

Simoes E, Kronenthaler A, Emrich C, Rieger MA, Rall KK, Schffeler N, Hiltner H, Ueding E, Brucker SY. Development of a provisional model to improve transitional care for female adolescents with a rare genital malformation as an example for orphan diseases. Biomed Res Int. 2014;913842. .

Pittock ST, Babovic-Vuksanovic D, Lteif A. MayerRokitanskyKsterHauser anomaly and its associated malformations. Am J Med Genet Part A. 2005;135(3):3146.

PubMed Google Scholar

Nationales Aktionsbndnis fr Menschen mit Seltenen Erkrankungen (NAKSE). Nationaler Aktionsplan fr Menschen mit Seltenen Erkrankungen. Handlungsfelder, Empfehlungen und Manahmenvorschlge. Bonn 2013. URL: (Zugriff: 02.08.2016).

Bodemann G. Welche Bedeutung haben Partnerschaft und Liebe fr Jugendliche heute? Eine deskriptive Untersuchung. Zeitschrift fr Familienforschung. 2003;15(3):91104.

Google Scholar

Statistisches Bundesamt (Hrsg.). Datenreport 2006. Zahlen und Fakten ber die Bundesrepublik Deutschland. Bonn 2006 (Bundeszentrale fr politische Bildung, Bd. 544).

Delaineb M, Ohl J. Activit sexuelle et qualit de vie chez les patientes atteintes dun syndrome de Mayer-Rokitansky-Kuster-Hauser. Gyncol Obsttr Fertil. 2014;42(12):86571.

Google Scholar

Statistisches Bundesamt. Bildungsstand der Bevlkerung. Wiesbaden 2015.

Shankar NL, Park CL. Effects of stress on students' physical and mental health and academic success. Int J School Educ Psychol. 2016;4(1):59.

Google Scholar

Simoes E, Sokolov AN, Kronenthaler A, Hiltner H, Schaeffeler N, Rall K, Ueding E, Rieger MA, Wagner A, Poesch LS, Baur M-C, Kittel J, Brucker SY. Information ranks highest: Expectations of female adolescents with a rare genital malformation towards health care services. PLoS ONE. 2017;12(4):e0174031.

PubMed PubMed Central Google Scholar

Simoes E, Sokolov AN, Graf J, Pavlova MA, Brucker SY, Wallwiener D, Schmahl FW, Bamberg M. Klinische Sozialmedizin -Warum? Von der epidemiologischen Assoziation zur personalisierten Sozialmedizin am Beispiel der Versorgung bei Mammakarzinom [Why Strive after Clinical Social Medicine? From Epidemiological Association to Personalized Social Medicine: a Case of Breast Cancer Care]. Gesundheitswesen. 2016;78(2):97-102.

Nahum GG. Uterine anomalies: How common are they, and what is their distribution among subtypes? J Reprod Med. 1998;43:87787.

CAS PubMed Google Scholar

Oppelt P, von Have M, Paulsen M, Strissel PL, Strick R, Brucker SY, Wallwiener D, Beckmann MW. Female genital malformations and their associated abnormalities. Fertil Steril. 2007;87(2):33542.

PubMed Google Scholar

Rare genital malformations in women's health research: sociodemographic, regional, and disease-related characteristics of patients with...

Recommendation and review posted by Bethany Smith

Blood test can predict the severity of COVID-19: Study – Free Press Journal

New York: Clinicians can examine COVID-19 patients' blood to identify those at greatest risk of severe illness and to pinpoint those most likely to need a ventilator, according to a new study.

The discovery could lead to new treatments to prevent deadly "cytokine storms" seen in severe cases of COVID-19. It also may help explain why diabetes contributes to worse outcomes in patients with the coronavirus.

The researchers from the University of Virginias (UVA) found that the levels of a particular cytokine in the blood upon diagnosis could be used to predict later outcomes.

Cytokines - proteins produced by immune cells - are responsible for severe overreactions by the immune system, known as cytokine storms, associated with COVID-19 and other serious illnesses.

"The immune response that we discovered to predict severe shortness of breath in COVID-19 is known in other pulmonary diseases to cause damage," said study researcher Bill Petri from the UVA.

"So this could lead to a novel way to prevent respiratory failure in individuals infected with the new coronavirus, by inhibiting this immune cytokine. We plan to test this in a model of COVID-19 prior to considering a clinical trial," Petri added.

For the findings, the research team identified 57 COVID-19 patients treated at UVA who ultimately required a ventilator. They then tested blood samples taken from the patients within 48 hours of diagnosis or hospital admission.

The research team compared the results with those from patients who did not wind up needing a ventilator. Cytokine storms, in which the immune system spirals out of control, are typically associated with an established group of cytokines.

But the best predictor of COVID-19 outcomes was an "underappreciated" cytokine more associated with allergies, the researchers reported. High levels of that cytokine, IL-13, were associated with worsened Covid-19 outcomes regardless of patients' gender, age or other health problems.

The researchers also identified two more cytokines associated with severe outcomes, though the duo had less ability to predict the need for a ventilator.

In addition, the researchers found that levels of two other cytokines were significantly higher in patients with elevated blood sugar. This "pro-inflammatory response," they said, may help explain why diabetes is associated with worse COVID-19 outcomes. In short, the body is primed to respond too strongly to the infection.

The researchers said the discovery could become part of a scoring system to let doctors flag at-risk COVID-19 patients for closer monitoring and personalized interventions. The finding also identifies cytokines doctors could target as a new treatment approach.

Read this article:
Blood test can predict the severity of COVID-19: Study - Free Press Journal

Recommendation and review posted by Bethany Smith

This Is What Happens to Your Brain on a Diet – MSN Money

There are countless dieting tips, tricks, recipes, and meal plans you can find in a single Google search, all promoting different ways to lose weight. But what you eatand how muchis affected by more than just your hunger, desire to control eating, or diet plan.

The first thing to understand when you want to lose a few pounds is something experts call your set-point weight: This is your body's "happy weight"it's a size that your brain and body try to maintain, and it includes the fat stores on your belly and elsewhere.

According to registered dietitian Dara Dirhan, this amount of fat becomes what the brain has determined to be the best for optimal function.

Two hunger hormones are responsible for trying to regulate your body's set point: ghrelin and leptin, says Dirhan. Ghrelin is known as the "hunger hormone" because it is secreted when the brain senses that available energy stores are running low.


This hormone generates feelings of hunger that convince you it's time to get some food in your belly. Your digestive system converts the calories to blood sugar (glucose), which can then power muscles, organs, the brain, and other cellular functions.

Leptin is known as the "satiety hormone"it's released when your body senses that you've eaten enough; it signals the brain that energy levels have been met.

These signals have three primary functions, according to David Prologo, MD, a dual board-certified obesity-medicine physician, and interventional radiologist. They tell your body when to seek food, when to slow down and conserve energy, and when to store and preserve fuel if it senses deprivation (a leftover from the days when famines weren't uncommon)and this is all in the name of survival.

The brain isn't concerned with how you look, Dr. Prolongo says. "It is concerned with maintaining life." Your body and brain are programmed to remain stable at your set point.

How your brain changes on a diet

When you first start a new dietor you aren't consuming enough energy for your brain's needsyou can experience symptoms like weakness, hunger, depression, fatigue, and headaches, among other symptoms. The good news is that after several weeks the brain eases up on these signals, Dr. Prologo says, as your body begins to find a new set point.

Jason McKeown, MD, neurologist and CEO of Modius Health, adds that once your body reaches a new set point, you'll see a reduction in your appetite and cravings. "To maintain results, diets in the long-term can influence this set-range, making your brain adapt and be comfortable at a lower weight," Dr. McKeown says. It's also possible to drive your set point upwards, he warns.

Changing your set point is no easy task: It can take months and sometimes even years, says Dr. McKeown, which is why you should set long-term diet and weight goals. "In the long run you could reset the weight range that your brain has established which will cause your body to speed up metabolism and decrease appetite, becoming comfortable with a lower weight," Dr. McKeown says. "Whereas in the short run, you may lose a few pounds, but youll often plateau and see the weight creep back up as its not enough to influence the weight your brain and body is happy with."

Food quality makes a difference

The quality of your diet is another variable. For brain health and well-being, Dirham recommends choosing a whole foods diet as much as possible. This means staying away from foods that have been processed or refinedenergy-dense, high-calorie foodsand incorporating healthier whole foods like fresh fruits and vegetables, lean meat, poultry, fish, and whole grains, Dirhan says.

Instead of focusing on what she calls a "calorie salary," stick to a whole food diet and practice mindful eating (slowing down your eating and taking time to appreciate meals). "This will make sure the brain is happy while aiding in weight loss," she says. (Focusing on calories is just one of many things keeping you from losing weight.)

Farrah Hauke, a psychologist in Scottsdale, Arizona who specializes in weight management and weight loss, believes that people are more likely to binge when they overly restricting what they eat. When people eat foods higher in fat or sugar, the brain releases "feel-good" chemicals that make the indulgence more rewarding. "We don't see this same brain stimulation with foods such as broccoli and grilled chicken breast," Hauke says.

When you diet, you can lose out on those feel-good chemicals, which means you're less likely to get those brain-boosting rewards from dieting. Hauke recommends you find other ways to reward yourself and feel satisfied; the goal is to avoid what she calls "cognitive distortions"negative thinking patterns that contribute to the common all-or-nothing diet approach.

The experts all agree that rigid rules, unrealistic expectations about eating, and fad diets aren't the best strategies for your body and brain. Instead, focus on the quality of your diet, listening to your body's hunger cues, and adding in physical activity. This, along with these tiny changes, can help you lose weight.

Gallery: 101 Ultimate Weight Loss Tips for Summer 2020 (Best Life)

Originally posted here:
This Is What Happens to Your Brain on a Diet - MSN Money

Recommendation and review posted by Bethany Smith

An Explosive Workup for Diarrhea: The Cascade Effect From an Incidental Finding on a Laboratory Panel – AAP News

A 19-month-old boy with a medical history of 1 febrile seizure presented to the emergency department (ED) with 2 days of vomiting and 1 day of diarrhea. He was accompanied by his nonEnglish-speaking mother, who reported several episodes of nonbloody, nonbilious emesis and dark brown, watery stools. The patient had decreased intake of solid foods, but he had been breastfeeding well. Because of his diarrhea, the patients mother was unsure how many voids he had had in the past day. He had not had fevers. The family history was significant for the patients father recently being diagnosed with hepatitis C. The patients mother brought him into the ED because of his symptoms and concern that he looked yellow.

In the ED, the patient was afebrile with normal vital signs for his age (including heart rate of 146 beats per minute), and he was well appearing and active with moist mucous membranes and a capillary refill of <2 seconds. However, the ED provider additionally documented that the patient appeared moderately dehydrated [and] slightly jaundiced, and he ordered a comprehensive metabolic panel (CMP). All values were within normal limits, including total bilirubin, except for a low bicarbonate of 16 mmol/L (normal 2130 mmol/L) and an elevated alkaline phosphatase (ALP) of 926 U/L (normal 129291 U/L). The provider consulted endocrinology for the elevated ALP, who noted a broad differential for elevated ALP and that transient hyperphosphatasemia is a diagnosis of exclusion. They recommended checking 25-hydroxyvitamin D, phosphate, and parathyroid hormone to

Original post:
An Explosive Workup for Diarrhea: The Cascade Effect From an Incidental Finding on a Laboratory Panel - AAP News

Recommendation and review posted by Bethany Smith

Sherlock, binx to develop point-of-care Covid-19 test using CRISPR technology – MedCity News

The first company to win a Food and Drug Administration authorization for a CRISPR-based product is now, less than two months later, looking to develop an on-site diagnostic for Covid-19.

Cambridge, Massachusetts-based Sherlock Biosciences said Wednesday that it would partner with binx health, based in Boston, to develop a point-of-care test for Covid-19 using CRISPR technology. Sherlock received an emergency use authorization for its CRISPR-based Covid-19 test kit on May 7, becoming the first company ever to get a regulatory nod for a product using the gene-editing platform.

The companies will use Sherlocks CRISPR technology and binxs molecular testing system, called io, to develop a way to test for Covid-19 in retail and similar settings.

This collaboration with binx health to advance our Sherlock diagnostic platform and offer an accurate, point-of-care test is the next critical step in combating the global Covid-19 crisis, Sherlock CEO Rahul Dhanda said in a statement. We are also excited to explore with binx how to utilize the io platform to bring accurate and affordable testing to hospitals, urgent care centers and other healthcare facilities for a range of diagnostic tests beyond Covid-19.

Testing for Covid-19 whether RT-PCR or serological relies on samples being sent to central laboratories from the point of care, meaning it can take several days before patients learn whether or not they have the disease days in which they could still spread the virus if they do not self-isolate. That has led to an interest in point-of-care testing. However, the Food and Drug Administration has come under fire for granting an emergency use authorization for one rapid test, Abbotts ID NOW, amid reports that it is delivering inaccurate results.

Sherlock was co-founded by Broad Institute scientist Feng Zhang, one of the pioneers of CRISPR technology. Another company, South San Francisco, California-based Mammoth Biosciences whose technology is based on the research of fellow CRISPR pioneer Jennifer Doudna of the University of California Berkeley is partnered with GlaxoSmithKline to develop a CRISPR-based Covid-19 diagnostic.

Photo: jxfzsy, Getty Images

Read more:
Sherlock, binx to develop point-of-care Covid-19 test using CRISPR technology - MedCity News

Recommendation and review posted by Bethany Smith

A New 20-Minute Covid-19 Test Will Use CRISPR Gene Editing Technology To Deliver Results At The … – The Herald

The Herald

John CumbersSherlock Biosciences is partnering with binx health to not only bring to market the first point-of-care CRISPR product but also take the first step toward a new paradigm in health and diagnostics.

On January 4, 2018, Boston was shut down by a blizzard, but Rahul Dhanda was on a mission. A few months prior, the veteran of the diagnostics industry had gotten a call from David WaltHarvard professor and scientific founder of biotech heavyweight Illuminaabout a potential startup company Walt was exploring with synthetic biology pioneers Feng Zhang and Jim Collins. Despite the weather, Dhanda, in his business jacket and snow pants, trudged through two feet of snow to pitch his vision for that company to its founders. The day ended with dinner and one takeaway: Lets do it.

That company is Sherlock Biosciences, and just two years after that fateful January day, it received the first FDA Emergency Use Authorization for its CRISPR-based Covid-19 test, and was named a Technology Pioneer by the World Economic Forum.

Today, Sherlock announced that it has partnered with binx health to scale the rapid diagnostic test for point-of-care settings ranging from doctors offices to grocery stores. It represents not only the first point-of-care CRISPR product to come to market, but the first step toward a new paradigm in health and diagnostics.

Sherlocks namesake diagnostics platform, Specific High-sensitivity Enzymatic Reporter unLOCKing, is a technique that uses CRISPR to identify highly specific genetic sequences. Its the perfect tool for diagnosing Covid-19 by the presence of the novel coronavirus, which is discernible by its specific RNA sequence. The CRISPR system is adapted from the bacterial immune system and is best known for its ability to edit genes. Typically, CRISPR uses a piece of guide RNA as a WANTED poster to seek out a target gene of interest, which is then snipped by its enzymatic partner, the Cas9 molecular scissors.

The incredible precision of CRISPR has revolutionized gene editing. That same specificity also makes it a powerful tool for diagnostics, which is vital in fighting pandemics. While SHERLOCK does not utilize Cas9, it employs the same underlying principle of enzymatic molecular scissors. Guide RNA strands serve as scouts for a specific sequence of genetic material. When the guide meets the virus, the enzymatic scissors are activated and chop up a reporter-probe-quencher sequence, generating a fluorescent signal that shows the presence of the virus.

When run in the lab, Sherlocks diagnostic process produces results in under an hour. The companys new partnership with binx will scale the technology and bring the testing time down to as little as 20 minutes.

binxs FDA-approved and point-of-care testing system, binx io, is an easy-to-use desktop-sized instrument that has already made waves in testing for sexually transmitted infections. With its single-use cartridge system and the SHERLOCK platform installed, a binx io unit can analyze nasal swab samples and report a detected or not detected result for the novel coronavirus in under 30 minutes.

The speed and performance of binx io makes it incredibly competitive and best-in-class, says Dhanda. The decrease in time and increase in performance of SHERLOCK in conjunction with binxs platform creates an incredibly powerful way to manage the pandemic. By providing diagnostic screening in everyday locations, binx and Sherlock are meeting a need for Covid-19 testing that remains highly urgent months into this pandemic, especially as case counts continue to rise in the United States.

Pivoting to conquer a pandemicThe team at Sherlock recognized early this year that the health crisis unfolding in China would soon become a global threat. Within a matter of days, the Board of Directors made a unanimous and resounding decision to alter course to combat Covid-19. Sherlocks scientists responded with an inspiring demonstration of commitment, adaptability, and creativity. This quick turnaround to mitigate such a pressing problem speaks to the vast potential of Sherlock as a company.

Never in my career have I worked at a company able to pivot so quickly in the way we have with this technology to work on Covid-19, remarked Dhanda. Everyone here is smart enough to do something else, but theyre here because they want to be scientists making an impact and they believe in making a difference in healthcare. I was impressed with how we went from vision to implementation almost overnight, and how quickly that happened really speaks to the culture of the company.

In commercializing the worlds first FDA-authorized CRISPR product, we are learning about the value of rapid, rigorous execution for realizing the translational potential of engineering biology, adds Dr. Jim Collins. Our team at Sherlock Biosciences was remarkable in their demonstrated ability to go beyond ideas, concepts and academic papers, to a developed, authorized Covid-19 diagnostic test that is supported by extensive data and strong corporate partnerships.

The logistics side of the equationsupply chain, distribution, partners, regulatory compliance, and morealso seemed to fall into place in response to the Sherlock teams sheer drive and resilience. These were potential hurdles that Dhanda, in a pre-pandemic world, had given himself two years to overcome, but the swift repurposing of research also catalyzed delivery to market. The result has been a profound ripple effect throughout the diagnostics space.

Reimagining diagnostics, screening populationsTo date, Americas approach to Covid-19 testing has followed general trends in diagnostics. The scarcity of Covid-19 tests has forced healthcare providers to triage potential patients, prioritizing symptomatic individuals to confirm likely positive cases. While valuable and necessary, it is rare for these diagnostic results to make a difference in clinical care for patients, nor does such limited testing help researchers understand this deceptively complicated disease in a variety of populations.

The high-throughput testing facilitated by SHERLOCK and binx is an incredible way to deliver results that were inconceivable even five years agowere breaking the mold, says Dhanda. We tend to make decisions based on limited access to resources, and diagnostics have always been rationed. Covid-19 has just put a magnifying glass on that. But the unique restrictions placed on this industry start to fall away when we have new ways of getting results.

For Dhanda and Sherlock, the answerfor Covid-19 and beyondis moving away from reactive triage testing and towards broad-based screening, which allows researchers to better understand how a disease behaves in people and spreads throughout a population. Sherlock is uniquely poised to continue facilitating this shift to broad-based screening. In addition to the CRISPR-based SHERLOCK, the companys other technological cornerstone is the cell-free synthetic biology platform INSPECTR (Internal Splint-Pairing Expression Cassette Translation Reaction). INSPECTR shows great promise in the at-home testing market, thanks to its low cost, room temperature, and modular implementation..

[INSPECTR and SHERLOCK] are highly programmablewe can direct these tools towards anything wed like, explains Dhanda.

An at-home Covid-19 test through INSPECTR, while not yet a reality, is just one of many possibilities for the platform. INSPECTRs single-base specificity and rapid results could allow for crucial differentiation between influenza variants, drastically reduce the spread of infectious disease, add value to oncology, and even revolutionize non-medical industries such as agriculture and industrial testing. Much remains to be seen, but one thing is for certainwith the diagnostics market on the cusp of a transformation, Sherlock Biosciences is the company to watch.- Forbes

Original post:
A New 20-Minute Covid-19 Test Will Use CRISPR Gene Editing Technology To Deliver Results At The ... - The Herald

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares – Yahoo Finance

ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 964,285 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $450.0 million, excluding any exercise of the underwriters option to purchase additional shares. The offering is expected to close on or about July 6, 2020, subject to customary closing conditions.

Goldman Sachs & Co. LLC, BofA Securities and Jefferies are acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners are acting as co-managers for the offering.

The common shares will be offered and sold pursuant to the Companys previously filed automatically effective shelf registration statement on Form S-3 (File No. 333-227427) filed with the U.S. Securities and Exchange Commission (the SEC) on September 19, 2018. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 29, 2020. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SECs website at A copy of the final prospectus supplement may be obtained, when available, from Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at; from BofA Securities by mail at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at; or from Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the expected closing date, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in CRISPR Therapeutics Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 12, 2020, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent CRISPR Therapeutics views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Story continues

Investor Contact:Susan

Media Contact:Rachel EidesWCG on behalf of CRISPR+1

Read more:
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares - Yahoo Finance

Recommendation and review posted by Bethany Smith

CRISPR Technology Market Segmentation, Industry Growth and Competitive Landscape Trends Forecast 2020-2029 | By MarketResearch.Biz – NJ MMA News

The Global CRISPR Technology Market 2020 Research Report is a professional and detailed study about the current and forecast state With COVID 19 Impact Analysis of the market.

MarketResearch.Biz offers a 360-degree view of the global CRISPR Technology market and offers accurate forecasting and also covers competitive landscapes, with in-depth market segmentation including type segment, industry segment, channel segment etc., vital trends and strategic recommendations to enable our clients. It also includes different clients data, which is very crucial for the manufacturers.

The historical information of the global CRISPR Technology market and evaluate the present market scenario based on the key factors determining the trajectory of this CRISPR Technology market with the help of primary and secondary data, the CRISPR Technology market research report projects the future and makes valid prediction. Moreover, the CRISPR Technology industry research report also incorporates insightful information from industry specialists to uplift readers to make well-informed business desicion. The CRISPR Technology market report also uses SWOT analysis and Porters five forces analysis to shed light on the important elements of the CRISPR Technology Market.

CLICK HERE !! To Know What Is The Impact Of COVID 19 On CurrentCRISPR Technology Market And How Market Will Grow In The Upcoming Period 2020-2029?

(***Our market experts are working day and night to identify, collect and timely deliver analysis on impact of unparalleled decisions of corporate executives in COVID-19 calamity on many businesses, their clients and their clients clients. We obeisance everyone who is doing their work in this economic and healthcare pandemic. Cordially Get in Touch for More Details Information.)

The report includes an reckoned impact of strict standards and regulations set by the government over the CRISPR Technology market in the forecast years. The market report also includes thorough research done using several analytical techniques such as SWOT analysis to identify the market growth pattern.

-We Do Offer FREE Sample Copy of this report. Kindly go through the following information in order to access the report.

** Note This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by MarketResearch.Biz

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures:

Major Players Are:

Thermo Fisher Scientific Inc, Cellecta Inc, GeneCopoeia Inc, GenScript Corporation, Merck KGaA, New England Biolabs Inc, Horizon Discovery Group, Origene Technologies Inc, Agilent Technologies Inc and Integrated DNA Technologies Inc

Market Segmentation:

Segmentation on the basis of product: Library, Plasmids and Vectors, Proteins, Others (Control Kits and gRNA). Segmentation on the basis of application: Biological Research, Agricultural Biotech, Industrial Biotech, Therapeutics and Drug Discovery

Regions & Countries Mentioned In The CRISPR Technology Market Report:

North America ( United States)

Europe ( Germany, France, UK)

Asia-Pacific ( China, Japan, India)

Latin America ( Brazil)

The Middle East & Africa

Some of the questions related to the CRISPR Technology market addressed in the report are:

With the developing demand, how are market players aligning their activities to fulfill the demand?

Which place has the most favorable regulatory rules to conduct commercial enterprise in the present CRISPR Technology market?

How has technological advances inspired the CRISPR Technology market?

At present, which organization has the very best market share in the CRISPR Technology market?

What is the maximum lucrative income and distribution channel used by market players in the worldwide CRISPR Technology market?

The market study bifurcates the worldwide CRISPR Technology market on the basis of product type, regions, application, and end-user industry. The insights are backed with the aid of accurate and easy to understand graphs, tables, and figures.

Role of CRISPR Technology Market Report:

Save and decrease time sporting out entry-level analysis by evaluatng the growth, size, key players and segments in the global CRISPR Technology Market.

Highlights vital business priorities in order to help companies to realign their business strategies.

The crucial findings and recommendations focuses key progressive industry trends in the CRISPR Technology Market, thereby allowing players to build effective long term strategies.

Develop/modify business growth plans by using substantial expansion offering developed and emerging markets.

Scrutinize detailed worldwide market trends andoverview coupled with the factors driving the market, as well as those inhibit it.

Intensify the decision-making process by understanding the strategies that support commercial interest with admire to merchandise, segmentation and industry verticals.

Any Query? Feel Free To Inquiry Here:

Table of Contents

Outlook of the CRISPR Technology Market: This section covers the key manufacturers, market segments, study aim and analysis of market size for the 2020-2029 forecast period.

Presumption and Growth Trends Highlighted until 2029: This prospects based on 3 section such as growth rate of key producers, industry trends, and manufacturing estimation.

CRISPR Technology Player Market Share: This consist player production, revenue, and price calculation at the side of other chapters, such as growth plans and mergers and acquisitions, products include with the aid of top players and served areas and headquarters distribution.

Market size: Size of the market includes analysis of price, market share of the production value and market share of production.

Company profiles: Here, new entrants and leading players in the CRISPR Technology market are analysed based on gross margin, revenue, sales area, vital products, price and production.

CRISPR Technology Analysis of the market value chain and sales channel: Covering analysis of distributor, value chain, customer and sales channel.

Market forecast: In this part of the report, the analyst have targeted on the forecast of the value of production, the forecast of consumption by region, the forecast of production by region, the forecast of manufacturing and earnings and the regional forecast.

Request The Complete TOC Of This Report:


Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

Address: 420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876


Read more:
CRISPR Technology Market Segmentation, Industry Growth and Competitive Landscape Trends Forecast 2020-2029 | By MarketResearch.Biz - NJ MMA News

Recommendation and review posted by Bethany Smith

Five things for pharma marketers to know: Thursday, July 2, 2020 – Roundup – MM&M – Medical Marketing and Media

The vaccine from Pfizer and BioNTech has shown potential in human trials. In a small trial, participants developed higher levels of COVID-19 antibodies than typically seen in infected people. (Reuters)

Sherlock Biosciences has partnered with Binx Health to scale its CRISPR-enabled COVID-19 test. The company plans to make the test available at the point-of-care and in other places like grocery stores, making it the first CRISPR product to come to market. (Forbes)

Submit a cover design for MM&Ms Hall of Femme issue. Design a cover that celebrates the inspirational women who are leading the industry, raising their voices and exerting their influence to make real change happen to enter the contest. The deadline is July 31. (MM&M)

Some government COVID-19 research contracts do not require the drug to be affordable. A report found some contracts allowed companies to bypass laws that ensure taxpayer-funded treatments or vaccines are affordable. (STAT)

Drug companies are suing to block a Minnesota insulin law. The law, which was to go into effect Wednesday, would allow patients to get insulin for $35 and was intended to stop people from rationing the drug because they couldnt afford it. (STAT)

View post:
Five things for pharma marketers to know: Thursday, July 2, 2020 - Roundup - MM&M - Medical Marketing and Media

Recommendation and review posted by Bethany Smith

Cell Therapy For Solid Tumors – Contract Pharma

Base editing, a new player in the gene editing arena, could have an important role in the development of immune-based cell therapies to treat solid tumors. Using cell therapies, such as CAR-T cells, in solid tumors remains challenging: the current word on the street is that such chimeric antigen receptors (CARs) will need multiple gene modifications to make them efficient and it is in this space that base editing could have a substantial advantage.Immune-cell-based therapy is an exciting cell therapy approach to treat cancer where the natural defenses of a patients immune system are used to target and kill cancer cells. Hopes were high following the initial FDA approvals of the first autologous CAR-T therapies for Novartis KYMRIAH (Aug 2017) and Gilead/Kite Pharmas YESCARTA (Oct 2017), both for blood-based cancers, but translating these successes into solid tumors remains a challenge. This is a consequence of the complexity and heterogeneity of solid tumors together with the immune inhibitory nature of the tumor microenvironment.For T cell-based therapies to work, the patient is treated with modified T cells that are rendered capable of identifying and killing tumor cells and, through this, generating a wider immune response against the tumor. Two key approaches used to modify T cells are through expressing a T cell receptor (TCR) known to target the tumor cell or a CAR. Other approaches include using and/or modifying natural killer cells, gamma delta cells or tumor infiltrating lymphocytes. It is not clear which approach will provide the most effective treatment option and in fact it might be that each tumor type responds better to one approach or to a combination of approaches. Irrespective of the approach, it is clear that the current therapies all face similar challenges; the risk of graft vs host disease (GvHD), a lack of durable remissions, on-target or off-target toxicity and cytokine release syndrome.Another layer of complexity for T cell-based therapies lies with the source of T cellsusing the patients own (autologous T cells), or a donor or iPSC-derived T cells (allogeneic). Each approach has advantages and challenges. Briefly, autologous treatments are attractive because they mitigate the risk of immune rejection and GvHD when infused back into the patient. However, they require a complex manufacturing process that necessitates specialist equipment local to the patient to enable the isolation of their T cells followed by rapid manufacture to transform them into engineered T cells ready to infuse back into the patient. At all points during this manufacturing pipeline, the product must be kept sterile and tracible to ensure the correct cells are transfused back into the correct patient. The allogeneic T cells approach is appealing because of the possibility that these could be engineered to be universal donor cells (suitable for all or most patients). Such cells can be manufactured in bulk and administered to multiple patients all over the world. This bulk manufacturing would attract cost-savings once a critical mass of therapy is reached. It could also allow for engineered T cells to be available on-tap to any patient, a game-changer for particular patients whose own T cell count is either too low for engineering, or that transduce poorly with the engineered construct during manufacture. The challenge for allogeneic T cell therapies is the ability to generate cloaked T cells that do not provoke an immune-response in the patient, as this could kill the engineered T cells after transplantation such that they have no efficacy or potentially lead to the death of the patient as a result of a disseminated cytokine storm. Despite these challenges, in April 2019 the US Food and Drug Administration (FDA) approved the first allogeneic CAR-T for investigational use in patients with multiple myeloma and more are expected to follow.To try and achieve a stealth allogeneic T cell that flies under the radar of the patients immune system, genetic engineering is key. Although T cells can be engineered to express a specific TCR or CAR, additional genetic changes are required to provide a cloak of invisibility, prolong the survival of the cells in the patient and enable them to function in an immune suppressive tumor microenvironment. From a simplistic point of view, one could view the modified CAR or TCR as a sat nav, with the T cell being the engine. You need both to get to your destination and, if youre able to improve your engine, its possible the outcome could be achieved faster and in a more reliable fashion. There are several gene knockouts or gene knockdowns that are seen as a natural first step to improving the properties of engineered allogeneic T cells and these are summarized in the table below:As there are multiple gene knockout options, a gene engineering technology capable of making multiple gene edits with as few off-target effects as possible is needed. Indeed, it is conceivable that an effective allogeneic T cell-based therapy might require ten or more gene edits.This prompts the question What is the best gene editing platform or technology to support multiple gene edits? On the surface of it, and owing to its phenomenal adoption in research labs worldwide over the past decade, most currently use the gene editing approach provided by CRISPR-Cas9. CRISPR was first commercialized in 2012 and quite staggeringly made its debut in a clinical trial for cell therapy in June 2016. Although CRISPR is an efficient gene editing tool, its mode of action of generating double-strand breaks in the DNA could be a source of concern. DNA double-strand breaks, which tend to be repaired by the cells repair machinery in an error prone fashion, can cause unintended changes in the genome of engineered cells. Although there are methods for minimizing these off-target effects when single genes are targeted, targeting multiple genes in one cell all at the same time could lead to genome-altering insertions, deletions and/or chromosomal translocations. The impact of this on a patient could be that the cell therapy is effective but the off-target genetic changes lead to deleterious side-effects, impacting patient recovery and potentially survival. Well-known alternatives to CRISPR include transcription activator-like effector nucleases (TALENS) and zinc finger nucleases (ZFN). These approaches have slightly different safety profiles to CRISPR and while optimized for single gene edits or knockouts, multiple gene knockouts still present a challenge for these technologies. Freedom to operate using these technologies in the therapeutics space can also be challenging, particularly for start-up and biotech companies.The potential deleterious impact of off-target effects, particularly for multiple gene edits has opened the door to a newcomer on the gene engineering scene: base editing. This technology first gained prominence from peer-reviewed papers published by researchers from Harvard University.1 Others, such as Rutgers University, have also developed base editing platforms.2 In brief, base editing uses a deaminase enzyme to make a specific base pair change in the DNA. The base pair alteration can either be an A to G or a C to T depending on which deaminase is used. Importantly, the CRISPR-Cas system is used to guide the deaminase to the base pair that is going to be altered, but in this version of CRISPR-Cas, a DNA double-strand break is not made, meaning that the off-target effects with base editing in terms of insertions, deletions or translocations should be substantially reduced.On the surface, this crucial characteristic makes base editing an excellent choice of gene editor for cell therapyit can be used to specifically knock-out multiple genes through the introduction of stop codons or splice site disruptions with limited capacity to introduce substantial, large-scale chromosomal abnormalities. However, as base editing was first published in May 2016,1 substantial research is required to understand fully the utility of base editing in the therapeutic space and to appreciate its advantages and challenges compared with standard gene editing approaches, such as CRISPR-Cas, TALENs and ZFNs.As is somewhat expected of a fashionable area for scientific research, the gene editing space does not stand-still for very long: Prime editing has followed hot on the heels of base editing. Unlike base editing, which makes changes to specific base pairs in the DNA, prime editing allows changes to be made to a run of base pairs by forcing the cell to use a DNA copying system that exists naturally in cells as part of the DNA repair mechanism. Initial data suggest3 that prime editing has higher off-target effects compared with base editing, in terms of introducing insertions and deletions, and more work is needed to understand the comparison and utility of base editing vs. prime editing. It will be interesting to see how prime editing evolves over the months and years within the cell and gene therapy space.Although cell therapy has demonstrated its potential for driving complete remissions in some patients with hematological cancers, the next big step is to translate these early successes into patients with solid tumors. However, due to the complexity of solid tumors, this is not a simple or straight-forward process and multiple factors need to be considered. While the sat nav in the form of an engineered TCR or CAR is crucial, the T cell engine could be the natural starting point for improving efficacy in patients with solid tumors, as could the use of allogeneic rather than autologous approaches. The multiple edits that will be needed to deliver a stealth, engineered, allogeneic off-the-shelf T cell are only now being investigated in earnest and it could be that the new kid on the block, base editing, provides a compelling route forward.References1. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420424. Doi:10.1038/nature179462. Horizon Discovery to provide access to novel base editing technology, January 2020; (accessed May 2020)3. Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149157. doi:10.1038/s41586-019-1711-4Dr. Jonathan Frampton is a business development professional who has been working for Horizon Discovery for the past 9 years and currently as their Corporate Development Partner. He is always scouting for exciting novel technology that could complement Horizons already extensive gene engineering toolkit. In addition to this he works closely with Horizons partners to manage out-licensing opportunities.

Cell Therapy For Solid Tumors - Contract Pharma

Recommendation and review posted by Bethany Smith

Analyst Activity Update on CRISPR Therapeutics AG (:CRSP) – Pineville

Wall Street brokerage firm analysts have placed aBuy rating on shares of CRISPR Therapeutics AG (:CRSP). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.30 on the shares. Based on a recent trade, the shares are hovering around $72.50 which, according to analysts, yield significant upside potential to the $75.88 consensus target price.

When it comes to investing in the equity market, discipline can play a major role in achieving ones goals. A few bad moves can send the investors confidence spiraling. Acting purely on emotion can lead to impulsive decisions that may cause the losses to pile up. Creating a solid plan and following through with the plan can help investors stay on track and focus on the proper details. Markets are constantly going up and down and the investing ride can sometimes be a bumpy one. Being able to see the big picture and focus on the important data can help keep the investor tuned in to the right channel. Investors who expect to jump into the market and immediately start raking in the profits may find out fairly quickly that trading without a plan can be a recipe for defeat.

Although the investing process is fairly straightforward, securing consistent returns in the stock market is not easy. Throwing hard earned money at un-researched investments can eventually lead the investor down the road to ruin. Every individual investor may have different goals when starting out. Aligning these goals with a specific plan can create a solid foundation for the future. Nobody can predict what the future will hold, but being aware of market conditions can be a great asset when attempting to navigate the terrain while mitigating risk. Once the vision of the individual investor is clear, the road to sustaining profits may be much easier to travel.

As company earnings reports continue to roll in, investors will be watching to see which companies hit their numbers for the last reporting period. Investors will also be watching which sectors are reporting the best earnings numbers. A positive overall earnings season could mean that the stock market could keep climbing. Many investors may be cautious with the market trading at current levels. Even though the gloom and doom prognosticators are out in full force, investors have to do the research and decide for themselves which way they believe the market will move in the next couple of months.

One of the most important factors that investors look at when examining stocks is the consistency of earnings results. When the quarterly earnings report is released, investors watch closely to see if the company is performing up to expectations. A company that fails to meet projections may see large price swings following the report. Of course one bad quarter may not signal trouble, but a company that continually disappoints during earnings season may need to be further examined to help figure out what is going on. Experienced investors will closely watch stock price movements before and after earnings events in order to gain a truer understanding of how the market is reacting to the reports.

Earnings estimates can also be manipulated, as the analysts are inclined to minimize them so that it increases the chances that a stock will beat the artificially lowered estimate in order to get inexperienced investors to buy.


CRISPR Therapeutics AG (:CRSP)s shares may have a significant upside to the consensus target of75.88, but how has it been performing relative to the market? The stocks price is 72.50 and their relative strength index (RSI) stands at 60.88. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.

Individual investors often strive to create a solid strategy before trying to take on the market. Setting up realistic, attainable goals, may be a good place for the amateur to start. There are many different approaches that the investor can take when getting into the stock market. Some investors will try to follow strategies that have worked for others in the past. Sometimes this will work, and sometimes it will not. Markets and economic landscapes are constantly changing. A strategy that worked yesterday may not work again tomorrow. Investors who put in the time to do the necessary homework may find themselves much better off when the market decides to rear its ugly head at some point down the road.

CRISPR Therapeutics AG (:CRSP) shares are moving-1.35% trading at $72.50 today.

See the original post here:
Analyst Activity Update on CRISPR Therapeutics AG (:CRSP) - Pineville

Recommendation and review posted by Bethany Smith

Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? – Cole of Duty

Analytical Research has added a new report to their increasing litany of reports titled Testosterone undecanoate Market Report. The new study encompasses valuable insights using a variety of graphs, tables and figures that explores opportunities, trends and drivers surrounding the Testosterone undecanoate industry.

HNY Research projects that the Testosterone undecanoate market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025.

Download PDF Sample of Testosterone undecanoate Market report @

By Market Players:Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, Zhejiang Xianju Pharmaceutical, Zhejiang Medicine Co.

By ApplicationPrimary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism

By TypeInjection, Oral

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Brief about Testosterone undecanoate Market Report with [emailprotected]

Points Covered in The Report:The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to PurchaseTo gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.Assess the production processes, major issues, and solutions to mitigate the development risk.To understand the most affecting driving and restraining forces in the market and its impact in the global market.Learn about the market strategies that are being adopted by leading respective organizations.To understand the future outlook and prospects for the market.Besides the standard structure reports, we also provide custom research according to specific requirements.

Single User License Copy and other purchase [emailprotected]

Table of Content

Chapter One: Industry Overview

Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis

Chapter Three: Production Market Analysis

Chapter Four: Sales Market Analysis

Chapter Five: Consumption Market Analysis

Chapter Six: Production, Sales and Consumption Market Comparison Analysis

Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis

Chapter Eight: Competition Analysis by Players

Chapter Nine: Marketing Channel Analysis

Chapter Ten: New Project Investment Feasibility Analysis

Chapter Eleven: Manufacturing Cost Analysis

Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers

List of Table and Figure

Figure Product PictureTable 2014-2019 Major Types Market Sales Volume And Market ShareFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateFigure 2014-2019 Sales Volume And Growth RateTable 2014-2019 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross And Gross MarginFigure 2014-2019 Capacity, Production And Growth RateFigure 2014-2019 Capacity, Production And Capacity Utilization Rate continued

If you have any special requirements, please let us know and we will offer you the report as you want.

Other Trending Report:

Global Shale Oil Market Status and Future Forecast 2015-2025 @

Note: Our report does take into account the impact of corona virus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

About us: Analytical Research Cognizance (ARC) is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448[emailprotected]

Originally posted here:
Testosterone undecanoate Market 2020 | What Will Be the Market Size and the Growth Rate Analysis by 2025? - Cole of Duty

Recommendation and review posted by Bethany Smith

Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market – Day Web Chronicle

Human chorionic gonadotropin (hCG) hails from the group of gonadotropin hormones and is normally delivered by the placenta. hCG hormone plays an essential job after the development of the embryo, and subsequently has increased huge footing throughout the years for the treatment of fruitlessness in ladies and men.

Sample Link Here:

By Therapeutic Area

By Technology

By End User

Growth in the frequency of male hypogonadism among the aged populace is the key factor driving the market development. Moreover, increment in footing picked up by hCG among healthcare experts and patients would enhance the market development. However, alerts and admonitions gave by the FDA relating to the symptoms of hCG treatment is anticipated to hamper the development of the market.

North America was the significant income contributor in 2017 and is foreseen to keep up its predominance all through the figure time frame.

Purchase Link Here:

Read more here:
Advancements in treatments in healthcare is boosting the Human Chorionic Gonadotropin (HCG) Market - Day Web Chronicle

Recommendation and review posted by Bethany Smith

Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 – Cole of Duty

With this new market research report namelyGlobal Hormone Replacement Therapy Market Growth 2020-2025we are accomplishing our aim of providing our clients an in-depth analysis of the global market. The report features a comprehensive analysis and enlightens market dynamics that provide a holistic picture of the global Hormone Replacement Therapy industry. The report offers knowledge about the industry competitors, growth potential, potentially disruptive trends, industry product innovations, market size value/volume (regional/country level, industry segments), and market share of top players/products. Growth figures are demonstrated between the forecast time-span using industrial facts and figures. The study comprises an analysis of market growth, consumption volume, market trends, and business price structures throughout the forecast amount from 2020 to 2025.

Some of the major Hormone Replacement Therapy market players are:Eli Lilly, Abbott, Pfizer, Novo Nordisk, Merck KGaA, AbbVie, Teva, Mylan, Novartis, Bayer, Roche, ANI Pharmaceuticals, Ipsen, TherapeuticsMD, Endo International,

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Recent Industry Trend:

The report shows the profiles of various prominent players in the global Hormone Replacement Therapy market. Different strategies implemented by these vendors have been analyzed and studied to gain a competitive edge, create unique product portfolios, and increase their market share. The report also throws light on major global industry vendors including essential vendors consist of both new and well-known players. Different strategies implemented by these vendors have been analyzed. The key insights have been covered to deliver a realistic overview of the industry, covering global Hormone Replacement Therapy market manufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc.

Following are the major regions considered for the analysis of the market: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Most important types of products covered in this report are: Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone

Most widely used downstream fields of market covered in this report are: Menopause, Hypothyroidism, Growth Hormone Deficiency, Male Hypogonadism, Other

Major Aspects Widely Described In The Report Are:

All segments of the global Hormone Replacement Therapy market have been covers in this study. The report highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion. The research report segments the geographical spectrum of this industry. The report provides market dynamics scenarios, along with growth opportunities of the market in the years to come.


What Insights Does The Hormone Replacement Therapy Market Report Provide To The Readers?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]

See the rest here:
Global Hormone Replacement Therapy Market 2020 Research by Business Analysis, Growth Strategy and Industry Development to 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack COVID-19 Antibody Test – PRNewswire

CARLSBAD, Calif., July 1, 2020 /PRNewswire/ --Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has submitted an official notification to the U.S. Food and Drug Administration ("FDA") to commence sales in the U.S. of the Company's FastPack SARS-CoV-2 IgGtest for COVID-19 antibodies. This test has already been submitted to the FDA for Emergency Use Authorization ("EUA"), but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test. Qualigen expects sales and shipments of the new test to begin in mid-July.

The FastPackCOVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2 IgG antibodies in bloodto identify individuals with an adaptive immune response to the virus that causes COVID-19, indicating recent or prior infection of the disease (which, as a practical matter, is believed to be indicative of immunity against re-infection). Qualigen's FastPacktest uses a specific protein that is also used by major diagnostics companies including Abbott Laboratories, Roche Diagnostics and Bio-Rad Laboratories in their COVID-19 antibody tests. The important advantage of FastPackover testing in large commercial laboratories, however, is its ability to deliver accurate results far more rapidly, in this case under 10 minutes, in physician offices, clinics and hospitals.

"Of the different options available, we chose to develop a test specific to the IgG antibody because IgG represents the long-term immune response. We believe our test's combination of high speed and high accuracy provides the clinician with more useful and actionable information than other testing approaches," Michael Poirier, the Company's CEO, explained. "We believe that reliable, yet convenient testing at the point-of-care is critical to helping combat this virus and get Americans back to their normal routines."

The new test is designed for use with Qualigen's new FastPack PRO System point-of-care diagnostic instruments. The FastPack PRO System is an upgraded version of Qualigen's flagship FastPack IP rapid immunoassay diagnostic point-of-care system.

Qualigen has been producing high-quality diagnostic testing products for almost 20 years, and has established a strong reputation for delivering highly accurate point-of-care tests that help save people's lives.

About the FastPack SystemThe FastPack System is a rapid and highly accurate immunoassay testing system consisting of the FastPack Analyzer and the FastPack test pouch (a single-use, disposable, foil packet that includes the FastPack reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care. Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders, antibodies against SARS-CoV-2, and research applications. Over the past 20 years, FastPack has generated more than $100 million in commercial sales. Qualigen's worldwide distributor for FastPack is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company; Sekisui, in turn, works with national distributors including McKesson Corporation and Henry Schein Inc.

About Qualigen Therapeutics, Inc.Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function, vitamin D status and antibodies against SARS-CoV-2. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit

Qualigen Forward-Looking StatementsThis news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the Company will be able to manufacture the FastPack Pro System instruments and SARS-CoV-2 IgGtest kits successfully; that any commercialization of the FastPack Pro System instruments and SARS-CoV-2 IgGtest kits will be profitable; that adoption and placement of FastPack Pro System instruments (which are the only FastPack instruments on which the Company's SARS-CoV-2 IgGtest kits can be run) will be widespread; that the Company's request to the FDA for Emergency Use Authorization will ultimately be approved; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company's drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products. Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Qualigen, Inc.


See the article here:
Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack COVID-19 Antibody Test - PRNewswire

Recommendation and review posted by Bethany Smith

How To Boost Your Immune System – 15 Tips From Experts – Women’s Health

Like most of us, Im doing my damnedest to stay healthy right now. Im social distancing and washing my hands almost obsessively. Im trying to eat as many vegetables as possible to ensure I'm getting health-supporting nutrients that I'm not exactly taking in via all the stress baking.

Its also not surprising that Ive been bombarded with news over the past few months about how to bolster my immune system. I cant scroll through my Instagram feed without seeing some influencer bragging about an immune-boosting smoothie or a supplement company promoting pills with elderberry and citrus.

Time-out, though. Immunity has a PR problem right now. The whole idea that you can power up your immunity in some quick-and-dirty way overnight (and, you know, avoid a cold or flu...or COVID-19) isn't actually how it works.

Think of immunity like this: If youre the star quarterback of your life, your immune system is like that super-jacked lineman whose number-one job is to protect you from all directions. And, separately (but still in that sports realm!), just like how strategic leadership can whip a team into shape, you can train your system to more efficiently pick off any opponentbug, virus, germthat comes your way. But that conditioning takes time and dedication.

So, taking a last-minute, reactionary approach to immunity is the opposite of how you should think about it, says Nicole Avena, PhD, visiting professor of health psychology at Princeton University. Immunity is a marathon, not a sprint. Because of that, there isnt any fast and easy way to immediately amplify yours. Youve got to take an all-in, holistic approach if youre going keep your immune system in fighting form, says Avena.

Recalibrating your immunity for the long game comes down to the classic health habits you hear time and time again: sleep, stress reduction, and sweating it out. The key is doing all of these to at least some degree and not expecting one to be the ultimate cure-all. You wont make your immune system healthier in a week by pumping yourself with vitamins because someone close to you is sick, says E. John Wherry, PhD, director of the Institute for Immunology at the University of Pennsylvania. But you absolutely can help your immunity by making certain lifestyle changes.

Nail Your Sleep Routine

Sleepspecifically getting at least seven hours most nightsmight be the Most Important Thing. The best data we have about how to improve immunity is on getting the right amount of good sleep, says Wherry. People who got six hours of shut-eye a night or less for one week were about four times more likely to catch a cold when exposed to a virus compared to those who got more than seven hours, according to a study published in the journal Sleep. (The risk of getting sick was even higher for those who snoozed less than five hours a night.)

Everything you do when youre awakeeating, digesting, working, walking, exercisingprompts your body to release inflammatory cells, says Rita Kachru, MD, section chief of the clinical immunology and allergy division and assistant professor at the David Geffen School of Medicine at UCLA. Sleep gives your body a break from all of that. Dont get hung up on one crappy night of Zs (or give yourself too much praise for one amazing one, for that matter); focusing on long-term, consistent good sleep habits is the way to go. Your building blocks, right here.

Mara de la Paz Fernndez, PhD, a sleep researcher and assistant professor of neuroscience and behavior at Barnard College of Columbia University

Mariana Figueiro, PhD, director of the Lighting Research Center and a professor of architecture at Rensselaer Polytechnic Institute

Mikka Knapp, a registered dietitian-nutritionist

Rebecca Robbins, PhD, a sleep researcher and co-author of Sleep for Success!

Megan Roche, MD, epidemiology researcher and Strava running coach

Its well established that stress prompts the release of cortisol, that fight-or-flight hormone that enables you to run for your life. When cortisol is high, your immune system isnt as active, says Daniel M. Davis, PhD, professor of immunology at the University of Manchester in England; your body sends all of its resources to the thing it thinks is most likely to kill you, and away from other stuff, like your protective network.

Dont stress? Ill just give up now, youre thinking. Stay calm and try this: Instead of attempting to eliminate negativity, refine the way you cope (with the genius advice ahead!)which will make the blues more manageable and mitigate that cortisol response, Davis says.

Joy Lere, a psychologist

Kevin Gilliland, PsyD, a clinical psychologist and executive director of Innovation360

Patricia Celan, MD, a psychiatry resident at Dalhousie University in Canada

Beatrice Tauber Prior, PsyD, a clinical psychologist

Working out creates inflammation in the body, but its the good kind, says Wherry. Its a little counterintuitive, because exercise actually disrupts your bodys homeostasis, he says. But when your sweat sesh is finished, your bod goes back to its status quokeeping your immunity on its toes in that brilliant way, he says. Research backs this up: Folks who exercise regularly develop more T cells (those destroyer white blood cells) than their sedentary peers, a recent study found. It also helps modulate the stress hormone cortisol, which, when raised, leads to inflammatory activity.

Some experts agree that overtraining (you know, that feeling when youve been pushing yourself too hard and youre feeling it) can hinder immunity. So if youre an everyday athlete, moderate exercise on a consistent basis is the end zone to aim for.

Jennifer Haythe, MD, a critical care cardiologist at Columbia University Medical Center

Lisa Ballehr, DO, an osteopathic physician and Institute for Functional Medicine certified practitioner

Ian Braithwaite, MD, an emergency physician at The Royal London Hospital

Kym Niles, certified personal trainer

Kristen Gasnick, board-certified physical therapist

Jenn Randazzo, registered dietitian

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Read more:
How To Boost Your Immune System - 15 Tips From Experts - Women's Health

Recommendation and review posted by Bethany Smith

Shock treatment, exorcism, psychotropic drugs: behind conversion therapy for queers – The Hindu

Rihaan* came out to his parents in the summer of 2008 three days after they created a profile for him on a matrimonial site. His conservative upper-class family in Pune reacted badly. There was confusion, rage, tears. My father begged me to meet a psychiatrist, who instantly diagnosed my condition as mother-fixation. Rihaans treatment started the same week. First it was coercion and counselling; then he was given medicines and dragged to brothels.

Then came the final sitting to reverse my orientation and cure the disorder. I was locked into a room wallpapered with pictures of nude men and they gave me some injections that made me throw up. I retched the entire day, collapsing in between, then waking up covered in vomit. Two days later the session was repeated and I was shown gay porn. Within a couple of weeks Rihaan was a defeated man. Panic rose in my chest even at the mention of same-sex attraction. My parents were summoned and officially informed that my conversion was complete. I lived like a zombie those days. I was heavily dependent on medicines and each time I tried to stop, I was ravaged by withdrawal symptoms. I contemplated suicide. Then, before I knew it, I was married to a cis woman.

Rihaans marriage lasted five months, but more than 10 years later, he still gets panic attacks. He has no career or confidence. I am unable to have a meaningful relationship and at times the shame and pain are unbearable, he says. Now, Rihaan is finally on the road to recovery.

Curing queerness

Not everyone is so lucky. Anjana Harish, the 21-year-old queer student from Kerala who was found dead in Goa last month, was also subjected to conversion therapy. Her friends say that Harish live-streamed a video revealing the torture she had to endure from pseudo-therapists.

Disturbingly, it looks like the discredited concept of conversion therapy is still being practised. Claiming to cure queerness, it can involve everything from shock treatment to exorcism and hormones to psychotropic drugs and kindling a sense of shame. According to medical experts, it causes irreparable damage to the mental health of victims.

Members of the LGBTQIA+ community say conversion therapy is practised in stealth. The patients are taken to psychiatric wards in hospitals or de-addiction centres with falsified files. When Jay*, a trans man from Ahmedabad, consulted a psychiatrist at a government facility for sex reassignment surgery, the doctor insisted that he go through conversion therapy first. I am a 43-year-old gazetted officer and I went there with some community members. If they could try to coerce me, think about what they must do to younger people with no support, says Jay.

Quacks and clerics

This so-called therapy is dished out not just by unscrupulous health professionals but also by preachers, naturopaths, shamans, and religious establishments. When Marie* told her parents in Coimbatore that she was a trans woman, they asked her to attend a course at an ashram the family used to frequent. On the second day of the course, I woke up in another place where I was held prisoner for two months, she says. I was slapped, body-shamed and sexually abused for being a sinner and acting against the divine plan.

Realising there was no point in fighting, Marie stopped reacting and convinced them that she had changed. I was sent home where I continued the charade for two more months. At the very first opportunity, I fled and never went back. Marie has since undergone sex reassignment surgery and works as a doctor in a hill station where nobody knows her past. I survived because I stayed vigilant from the beginning. Once they break your spirit, there is no going back.

Salmas* relationship with another girl became a scandal that rocked her hometown, Lucknow. It was a cleric who advised the family to keep her in isolation; she was raped multiple times by a close relative, a man she called kaka (uncle). In India, religious institutions and representatives play a big part in promoting conversion therapy. In the West, groups like Exodus International openly promoted conversion therapy across nearly 20 countries, but it has been more hush-hush here, with saints, pastors and babas doing it on the sly. Organised groups operate as de-addiction centres, prayer groups or ashrams.

Against the law

We condemn conversion therapy. Its unlawful, says P.K. Dalal, President, Indian Psychiatric Society (IPS). IPS has taken a strong stand against it. We have a protocol when it comes to such cases and we will soon be coming out with a statement, he adds.

Although there is no specific law prohibiting conversion therapy, legal experts emphasise that the practice violates the Right to Privacy enshrined under Article 21. If sexual abuse is involved, its an IPC offence anyway and now we have the Mental Healthcare Act, 2017, that gives a lot of agency to individuals, says Sandhya Raju, an advocate at the Kerala High Court and a member of the Human Rights Law Network. Once mental health review boards are constituted as part of enforcing the law, the community can use it to protect their rights.

If the practice is used against children below 18, the law is even more stringent. Parents can be booked under Section 75 of the Juvenile Justice Act, 2015. Prijith P.K., president of the Thiruvananthapuram-based Queerythm, which operates a 24x7 helpline for LGBTQIA+ people, says, Very often parents are involved, and doctors claim the treatment is for depression or schizophrenia. He thinks new legislation is needed to address the issue. While transpersons are protected under the NALSA judgment, other segments including gays, lesbians and bisexuals have no legal support. Same-sex marriages are still not legal in India. We talk about inclusivity and awareness, but legal backing is very important to achieve that goal. When the discrimination ends, the rest will follow, he says.

While most such practitioners are quacks, there are some who strongly believe they are offering a service. A Kerala-based psychiatrist who practises conversion therapy said, on condition of anonymity, that his patients undergo the treatment willingly as its easier to live as a heterosexual individual.

According to him, many of his patients now have a family and children. But he admits that many of them return due to marital discord and are on endless medication for depression.

A Hyderabad-based sexologist is equally confident. He offers different programmes tailored to the severity of queerness and says, You can fix most homosexuals with hormone therapy. Psychiatric interventions have been successful in most cases Ive treated. For example, testosterone injections can reverse same-sex desire to a great extent while some people respond to behavioural therapy.

He refuses to share his methods and says sexual deviance often springs from childhood sexual abuse and conditioning. He believes he is helping queer people by reaffirming their real orientation or gender identity, making them acceptable, and protecting the honour of their families.

Hypnotised, lobotomised

The origins of this clandestine practice date back to the 19th century, when deviant sexual orientations were considered sinful or criminal. One of the first documented cases comes from the accounts of Albert von Schrenck-Notzing, a German physician who reportedly used hypnosis to cure homosexuality in the 1890s.

By the early 1900s, practitioners worldwide began to use hypnosis as well as electroconvulsive therapy and sometimes surgical procedures like lobotomy. People were tortured, castrated and subjected to sordid corrective measures. Aversion therapy, of the kind Rihaan underwent, was portrayed in Stanley Kubricks 1971 film A Clockwork Orange.

In India, the Department of Psychiatry at AIIMS, New Delhi, conducted a study to reverse sexual orientation between 1977and 1982. The subjects were six homosexual people, who were administered electric shocks using an aversion therapy apparatus set at 50 volts to control their homoerotic fantasies. The report claimed that four persons were successfully reoriented. By the 2000s, several doctors and healers had popped up across the country.

In May this year, the U.N. published a report cataloguing the severe and everlasting impacts of conversion therapy. The report says, Attempts to pathologize and erase the identity of individuals, negate their existence as lesbian, gay, bisexual, trans or gender diverse and provoke self-loathing have profound consequences on their physical and psychological integrity and well-being. It urges governments to ban conversion therapy. So far only five countries Germany (for under-18s), Malta, Ecuador, Brazil, Taiwan have drawn up bills making it illegal, but efforts are on in other countries too.

At the most basic level, conversion therapy is unethical and a human rights violation. Even after the Supreme Court decriminalised consensual same-sex relationships by striking down Section 377 and came out with the historic NALSA judgment to protect transgender rights, Indian society is far from queer-friendly: LGBTQIA+ individuals still face violence, hostility and stigma. And a very real threat to their mental and physical health.

The Turing Effect

In January 1952, English mathematician Alan Turing, who played an important role in breaking German war codes during WW II,

was charged under the Criminal Law Amendment Act, 1885 for being in a sexual relationship with a man. Turing, who would later become famous as the father of modern computer science and artificial intelligence, was convicted. He was made to undergo hormonal therapy or chemical castration for one year, which reportedly made him impotent and led to the formation of breast tissue. Turing was also barred from continuing his government work.

In June 1954, two weeks before he turned 42, Turing was found dead at home, by apparent suicide, although subsequent reports claimed his death may have been due to accidental poisoning. Turings path-breaking research and his persecution were the subject of the 2014 Oscar-winning film, The Imitation Game, starring Benedict Cumberbatch. In December 2013, Queen Elizabeth II overturned Turings conviction. And in September 2016, the U.K. government said it would extend the retroactive exoneration to other men convicted similarly, under a new Alan Turing law.

*Names changed to protect identity.

Visit link:
Shock treatment, exorcism, psychotropic drugs: behind conversion therapy for queers - The Hindu

Recommendation and review posted by Bethany Smith

New Therapies may Offer Hope for Patients with Metastatic Breast Cancer – OncoZine

With more than two million new cases diagnosed in 2018, breast cancer is the most common cancer in women worldwide.[1] The disease represents about 25% of all cancers in women. Incidence rates vary widely across the world, from 27 per 100,000 in Middle Africa and Eastern Asia to 85 per 100,000 in Northern America. Breast cancer is also the fifth most common cause of death from cancer in women globally, with an estimated 522,000 deaths annually

An estimated 90% of all breast cancer is diagnosed at an early stage. [2] And approximately 70% of all breast cancers are HR+, HER2-, the most common subtype of the disease. [3] Even within this subtype, HR+, HER2- breast cancer is a complex disease, and many factors, including cancer which spread to the lymph nodes and the biology of the tumor, can impact the risk of recurrence. Recent data shows that about 30% of people diagnosed with HR+, HER2- early breast cancer are at risk of their cancer returning, potentially leading to incurable metastatic disease.[4]

Metastasized diseaseBreast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The malignant tumor is getting worse when the cells invade surrounding tissues or metastasize to distant areas of the body. In that case and in ths stage of breast cancer also referred to as stage IV breast cancer, spreads or metastasizes beyond the breast and nearby lymph nodes to other parts of the body. In the majority of cases, this includes the bones, lungs, liver, or brain.

Although an advanced disease, most women with metastatic or stage IV breast cancer are treated with systemic therapy. This treatment may include hormone therapy, chemotherapy, targeted therapy, or a combination of these options.

No an end-stage cancerWhile some people may refer to metastatic breast cancer as end-stage cancer, the disease is NOT hopeless and many people continue to live long, productive lives with breast cancer in this stage.

In an interview with The OncoZine Brief in December 2019, Susan Rafte describes her experience as a 25-year metastatic breast cancer survivor. While challenging, she became a peer-to-peer support volunteer through MD Anderson Cancer Center and has helped many patients with her peer support program. Rafte has also contributed to many research projects and committees as a patient advocate.

Listen to The OncoZine Brief: Susan Rafte: A 25+ Year Survivor of Metastatic Breast Cancer and Patient Advocate

A growing number of treatment optionsAnd while metastatic breast cancer may be treated in a different way than breast cancer diagnosed at an earlier stage, there is a wide variety of treatment options for metastatic disease. And investigators are studying new drugs in clinical trials.

Although metastatic breast cancer can be unpredictable, with hopeful times when patients are responding well to treatment and the disease is stable to scary time of progression, the result of ongoing research and development is that more and more patients are given the opportunity of living life to the fullest while, at the same time, being treated for metastatic disease.

Metastatic breast cancer can not be cured. But ongoing treatment may control the disease for a number of years. New treatment options may not only help patients live longer, but they can also help in relieving cancer-related symptoms, and improve the patients overall Quality of Life (QoL), something doctors describe keeping [the patient] feeling as good as they can for as long as they can. And Quality of Life, including issues related to sexual intimacy, is important for the overall health of patients as was demonstrated during a round table discussion with patients and physicians during the 2019 San Antonio Breast Cancer Symposium (SABCS).

With a growing number of treatment options, if one option fails, there is usually another option patients can try. For patients diagnosed with a metastatic disease today, there is, as a result, more hope for many years of good Quality of Life compared to patients diagnosed two decades ago. palliative

Listen to The OncoZine Brief: Candid Conversations on Mets, Sex, and Side Effects: a Panel Discussion With Breast Cancer Oncologists, Womens Health Experts, and Patients.

Clinical developmentClinical trials are an important step in establishing the safety and efficacy of potential new treatments. Clinical trials also help investigators decide if established side effects or adverse events as a result of a particular new treatment option are acceptable when weighed against the benefits of that particular treatment option.

But ongoing research is also instrumental in understanding breast cancer leading to a better understanding of the biology of the disease and help physicians to better (or earlier) detect and diagnose the disease.

According to the American Cancer Society, more than 1,000 investigational drugs are studies before just one makes it to clinical trials. And, on average, a new drug for the treatment of breast cancer may take 6 years and in some cases even longer before scientists begin are able to test a particular new drug in a clinical trial. And, the clinical trial process itself (from phase I to phase III and market approval) may add another 6 10 years to the development process.

ProgressEarlier this week, investigators at Oncolytics Biotech confirmed that they have dosed a first patient in the so-called phase II BRACELET-1 study (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti- PD-L1 and Paclitaxel; NCT04215146), a clinical trial designed to evaluating Pelareorep-based combination therapies in patients with endocrine-refractory, HR+/HER2- metastatic breast cancer.

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus, a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The investigational compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.

In the study, being conducted under a co-development agreement with Merck KGaA and Pfizer, participating patients receive paclitaxel, pelareorep in combination with paclitaxel alone, or pelareorep in combination with paclitaxel and anti-PD-L1 checkpoint inhibitor, avelumab (Bavencio).

The randomized, open-label, BRACELET-1 study is designed to support the results of a prior successful phase II trial (IND-213) that showed a near doubling of overall survival (OS) with pelareorep treatment, by demonstrating pelareoreps ability to induce a robust anti-tumor immune response in an identical patient population (patients with HR+/HER2- metastatic breast cancer).

The ability of pelareorep-induced immune responses to enhance anti-PD-L1 therapy will also be evaluated through the inclusion of the paclitaxel-pelareorep-avelumab combination therapy cohort. Importantly, the trial also aims to validate peripheral T-cell clonality as a biomarker of pelareorep response in HR+/HER2- metastatic breast cancerm, which may aid in future registrational trial study design and patient selection.

MonarchEAnother clinical trial, the randomized, open-label, phase III monarchE study, is designed to investigate abemaciclib (Verzenio; Eli Lilly and Company) in combination with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high-risk, node-positive, early-stage, hormone-receptor-positive, human epidermal receptor 2 negative, breast cancer. The study includes research on acquired genomic alterations in circulating tumor DNA (ctDNA)an area of particular interest as scientists try to understand how to individualize treatment for people living with HR+, HER2- advanced breast cancer.

Abemaciclib is an inhibitor of cyclin-dependent kinases (CDK)4 & 6, which are activated by binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4 & 6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation.

In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 to S phase of the cell cycle, resulting in senescence and apoptosis (cell death). Preclinically, Verzenio dosed daily without interruption resulted in a reduction of tumor size. Inhibiting CDK4 & 6 in healthy cells can result in side effects, some of which may be serious. Clinical evidence also suggests that Verzenio crosses the blood-brain barrier. In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

Investigators at Eli Lilly and Company recently presented data of a study of abemaciclib in combination with standard adjuvant endocrine therapy (ET) and confirmed that study has met the primary endpoint of invasive disease-free survival (IDFS), significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant ET alone.

These results are from a pre-planned interim analysis of the phase III monarchE study making abemaciclib the only CDK4 & 6 inhibitors to demonstrate a statistically significant reduction in the risk of cancer recurrence for people with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. The established safety profile was consistent with that observed in other abemaciclib studies in the MONARCH clinical program.

When a [patient] is diagnosed with high-risk early-stage breast cancer, they strive to do everything in their power to prevent a recurrence. And as clinicians, we have the same goal, noted Maura Dickler, M.D., vice president of oncology, late-phase development, Lilly Oncology.

The monarchE [trial] was intentionally designed for people whose breast cancer is at a high risk of returning. We are incredibly excited by the results of monarchE and that we can potentially offer a new treatment option for patients with high-risk HR+, HER2- early breast cancer. This would not have been possible without the tremendous commitment from the people who participated in this trial.

ManufacturingAbemaciclib is Lillys first solid oral dosage form to be made using a faster, more efficient process known as continuous manufacturing, a new and advanced type of manufacturing adopted by the pharmaceutical industry.

Continuous production, which is contrasted with batch production, is a flow production method used to manufacture, produce, or process materials without interruption. The production method is called continuous production because the raw materials, either dry bulk or fluids that are being processed, are continuously in motion, undergoing chemical reactions or subject to mechanical or heat treatment. One of the benefits of this approach is that it eliminates, or significantly reduces, the hold times in-between steps that are typical in batch manufacturing. Lilly was one of the first companies to use this technology on a large scale basis.

Antibody-drug ConjugatesHuman epidermal growth factor receptor 2 (HER2) is a gene that can promote cancer progression when mutated or expressed at high levels. High expression levels of HER2 have been observed in different cancer types, including breast cancer. Several HER2-targeted therapies are approved for the treatment of HER2-overexpressing breast cancer.

One of these agents is the HER2-targeted antibody-drug conjugate (ADC), fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo/AstraZeneca). The FDA-approval of the drug in late 2019, was based on the results of the registrational Phase II trial DESTINY-Breast01 of trastuzumab deruxtecan-nxki (5.4mg/kg) monotherapy in patients with HER2-positive metastatic breast cancer. All patients received prior trastuzumab, trastuzumab emtansine with the majority of patients (66%) receiving prior treatment with pertuzumab (Perjeta; Genentech/Roche).

The Phase II trial results showed a confirmed objective response rate of 60.3% (n=111, 95% CI 52.9-67.4) including a 4.3% complete response rate (n=8) and a 56.0% partial response rate (n=103). Median duration of response of 14.8 months (95% CI 13.8-16.9) was demonstrated as of 1 August 2019. [5] In addition, a median progression-free survival of 16.4 months (95% CI 12.7-not estimable), based upon a median duration of follow up of 11.1 months, was presented at the 2019 San Antonio Breast Cancer Symposium and published online in The New England Journal of Medicine.[6]

The approval oftrastuzumab deruxtecan underscores that this specifically engineered HER2-directed antibody-drug conjugate is delivering on its intent to establish an important new treatment for patients with HER2-positive metastatic breast cancer, noted Antoine Yver, Executive Vice President and Global Head, Oncology R&D, Daiichi Sankyo

Since the beginning of our clinical trial program four years ago, we have focused on the opportunity to transform the treatment landscape for patients with HER2-positive metastatic breast cancer, and we are extremely proud of how quickly we delivered Enhertuto patients in the US, as trastuzumab deruxtecan represents one of the fastest-developed biologics in oncology, Yver added.

In late May 2020, the drug was also approved in Japan.

Triple-negative breast cancerOne of the most difficult to treat forms of breast cancer is (metastatic) triple-negative breast cancer. Traditional breast cancer treatment options dont work because cancer cells in (m)TNBC cancer test negative for estrogen or progesterone receptors and dont make too much of the protein called HER2.

This disease, which accounts for about 10-15% of all breast cancers, is more common in women younger than age 40, African-American women, or women who have a BRCA1 mutation and differs from other types of invasive breast cancer in that they grow and spread much faster, have limited treatment options, and overall worse prognosis.[7]

In April 2020 a new treatment option for adult patients diagnosed with (metastatic) triple-negative breast cancer who have received at least two prior therapies for metastatic disease, received accelerated approval in the United States. The drug, sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy) developed by Immunomedics, is a Trop2-directed antibody conjugated to SN-38, the active metabolite of the topoisomerase I inhibitor, irinotecan. Trop2 is a cell-surface receptor that is over-expressed in epithelial cancers, including TNBC. In addition to breast cancer, the uniquely targeting agent is being studied in phase III trials for urothelial cancer, glioblastoma, endometrial cancer, and prostate cancer.

Listen to The OncoZine Brief: Sacituzumab Govitecan, a Novel Treatment for Patients with mTNBC

The confirmatory multicentre, randomized, phase III ASCENT trial, which compared sacituzumab govitecan versus the physicians choice of chemotherapy in patients with mTNBC who have failed2 prior lines of therapy, was stopped earlier than planned after an independent Data Safety Monitoring Committee confirmed compelling evidence of efficacy in the treatment of patients with mTNBC.

An ongoing phase III study is comparing sacituzumab govitecan with the physicians choice of chemotherapy in patients with HR-positive/HER2-negative metastatic breast cancer (NCT03901339; TROPiCS-02). In addition, a phase I/II trial (NCT04039230) is investigating the novel antibody-drug conjugates in combination with talazoparib (Talzenna; Pfizer), a oncedaily oral PARP inhibitor approved for the treatment of gBRCAmutated HER2negative locally advanced or metastatic breast cancer. In addition, a phase I/II, open-label, multicentre, randomized umbrella study (NCT03424005; Morpheus-TNBC) is evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations, including sacituzumab govitecan, in patients with mTNBC.

Precision oncologyPrecision oncology ensures that treatment is specifically designed and targeted to a specific form of cancer using a patients individual genetics the genes that are mutated and cause cancer to grow to create a personalized treatment protocol based on the genetic mutations. Such an approach may offer far better results with fewer side effects than standard chemotherapy.

Recently, two companies, Invitae Corporation and ArcherDX, confirmed that they entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.

The combined company is expected to help transform care for cancer patients, accelerating the adoption of genetics through the most comprehensive suite of products and services available. Integrating germline testing, tumor profiling, and liquid biopsy technologies and services in a single platform may enable precision approaches from diagnostic testing to therapy optimization and monitoring, expanding access to best-in-class personalized oncology.

Rucaparib and lucitanibClovis Oncology, presented four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs during the virtual meeting II of the American Association for Cancer Research (AACR), held June 22 24, 2020.

The presented data summarize findings from preclinical studies evaluating the pharmacokinetics (PK)/pharmacodynamics (PD) and anti-tumor activity of rucaparib, an oral, small-molecule PARP inhibitor in orthotopic and intracranial mouse models, and its synergy with CHK1 inhibition in tumor cell lines.

Additional presentations included findings from a study of the PK of lucitanib, an oral, potent inhibitor of tyrosine kinase activity, in a simulated patient population to inform dosing-regimen selection, and from a pre-clinical study evaluating the anti-tumor efficacy and mechanism of action of lucitanib in combination with a mouse ortholog of ALKS 4230, a selective agonist of the intermediate affinity IL-2 receptor, in a mouse colon cancer model. Lucitanib and ALKS 4230 are both development-stage compounds.

Data from our ongoing non-clinical studies underscore our commitment to pursuing innovative research that advances novel therapies for cancer patients, noted Patrick J. Mahaffy, President and Chief Executive Officer of Clovis Oncology.

In particular, we are pleased to present new, non-clinical data exploring the PK/PD of our PARP inhibitor Rubraca, evaluating the synergies of PARP and CHK1 inhibition in combination, as well as important data for lucitanib to understand optimal dosing and use in combination with other anticancer agents to treat solid tumors, Mahaffy added.

Modulating the effects of cortisolCorcept Therapeutics, a commercial-stage company developing novel drugs to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol, presented updated genomic data from patients with adrenocortical carcinoma at the 2020 American Association of Cancer Research (AACR) Annual Meeting.

Excessive cortisol in patients with adrenal cancer causes Cushings syndrome and may also blunt the efficacy of immunotherapeutic agents such as checkpoint inhibitors, said Andreas Grauer, M.D., Corcepts Chief Medical Officer.

The data we are presenting informed our Phase Ib trial of our proprietary, selective cortisol modulator relacorilant in combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda; Merck & Co) in patients with metastatic or unresectable adrenocortical cancer. Our trial examines whether relacorilant can, in addition to treating Cushings syndrome in these patients, also help immunotherapy achieve its maximum effect, by reducing the immunosuppressive effects of excess cortisol activity, Graucer concluded.

Clinical TrialsA Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study NCT04215146Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production NCT04373265.ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)

References[1] World Health Organization. Breast cancer: prevention and control. Online. Last accessed on June 20, 2020.[2] Howlader N, et al. SEER Cancer Statistics Review, 1975-2013. Online. Last accessed on June 20, 2020.[3] Howlader N, Altekruse S, Li C. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).[4] Reinert T and Barrios CH. Optimal Management of Hormone receptor-positive Metastatic Breast Cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20.[5] ENHERTU [fam-trastuzumab deruxtecan-nxki] US prescribing information; 2019.[6] Modi, S., et. al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. NEJM. December 11, 2019. DOI:10.1056/NEJMoa1914510.[7] Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741-751. doi:10.1056/NEJMoa1814213

Read the original here:
New Therapies may Offer Hope for Patients with Metastatic Breast Cancer - OncoZine

Recommendation and review posted by Bethany Smith

Denise Welch on her struggle with depression: ‘I feel grateful that I’m still standing’ –

Precisely 32 pages into The Unwelcome Visitor, Loose Women panellist Denise Welchs chatty, conversational account of living with clinical depression, my stomach abruptly swooped upwards before plunging into liftshaft freefall.

This was not the plan. Having suffered from debilitating depressive episodes on and off since my early teens, I have deliberately body swerved what I term Low Mood Literature on the Tolstoyan grounds that each unhappy person is unhappy in their own way and its actually quite tedious (sorry) to plough through other peoples usually quite niche travails.

But these days theres a celebrity out there for every mental health cohort; the drinkers, the thinkers, the wild swimmers, free runners, gardeners and agoraphobics all have their various champions.

Thats not a bad thing but it is A Thing. Former Labour spin doctor Alistair Campbell is due to publish his Living Better: How I Learned to Survive Depression and I can safely predict there wont be much crossover between the readership of his book and Welchs. But by God, there will be a readership for both in the wake of the Covid-19 pandemic.

Theres a mental health tsunami on its way, says Welch, speaking to me on the phone from her home in Cheshire. As lockdown eases off so many people will need treatment, but the NHS just hasnt got the resources. So what are they to do?

Self-help memoirs are a start. Welch has written two best-selling autobiographies but The Unwelcome Visitor: Depression and How I Survive Itis different. It concentrates on her tormented inner life rather than the relentlessly upbeat pocket-rocket persona she projected in public.

Welch thinks as she speaks as she writes; calling her depression the unwelcome visitor is her one and only foray into metaphor.

The likes of Stephen Fry and Ruby Wax have written very eloquently about their mental health battles, she says. My tribe wouldnt be drawn towards someone who was Oxbridge-educated. My book is aimed at Becky from Bolton.

She needs help too. So does her husband and her friends. They need to understand that she cant just pull herself together, that she cant control the pain. Im relatable. I dont have the answers. I am just telling my story, my truth and if I can help people then that will be my proudest legacy.

Welch was 31, a hugely popular soap star and self-confessed party girl when severe post-natal depression hit after the birth of her first baby, Matthew. It never quite left.

The next thirty-one years have been spent learning how to manage her Unwelcome Visitor, the grim reaper who appears unbidden, draining the colour, leeching the joy from her world.

I tell her that despite my best efforts, her plain prose reduced me to rubble. I felt, as a young person might say, triggered when I abruptly welled up with tears of recognition at her shameful, secret post-natal trauma.

I wanted my feelings back: just to be able to experience emotions again, especially for my baby; just to be normal, Welch writes in The Unwelcome Visitor.

Even though Im not religious in the least, I used to pray, Dear God, please, please, help me to love my baby.'

I had no inkling that I would be spirited back to the aftermath of a wretched labour in 2008 when I too felt desolate, empty, mad and as terrified as she was of being unmasked as a wicked, unnatural woman devoid of maternal feeling.

I literally couldnt bear to look at my desperately-wanted second daughter, with her unnervingly intense brown gaze. Instead, I would fix my own eyes on the middle distance while baring my teeth in a caricature of a smile so she wouldnt guess I was broken.

For her part, Welch recounts that years later, long after baby Matthew had grown up to become Matt Healy, singer in the achingly cool band the 1975, he wrote a song She Lays Down, that painfully captured the slow-motion horror of post-natal depression.

Denise Welch on her struggle with depression: 'I feel grateful that I'm still standing' -

Recommendation and review posted by Bethany Smith